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ABSTRACT

Ridder, Bradley J. Ph.D., Purdue University, May 2015. Modeling, Optimization, and
Sensitivity Analysis of a Continuous, Multi-Segmented, Multi-Addition Plug-Flow
Crystallizer for the Production of Active Pharmaceutical Ingredients. Major Professor:
Zoltan Nagy.

We have investigated the simulation-based, steady-state optimization of a new type of
crystallizer for the production of pharmaceuticals. The multi-segment, multi-addition
plug-flow crystallizer (MSMA-PFC) offers better control over supersaturation in one
dimension compared to a batch or stirred-tank crystallizer. Through use of a population
balance framework, we have written the governing model equations of population
balance and mass balance on the crystallizer segments. The solution of these equations
was accomplished through either the method of moments or the finite volume method.
The goal was to optimize the performance of the crystallizer with respect to certain
quantities, such as maximizing the mean crystal size, minimizing the coefficient of
variation, or minimizing the sum of the squared errors when attempting to hit a target
distribution. Such optimizations are all highly nonconvex, necessitating the use of the
genetic algorithm. Our results for the optimization of a process for crystallizing
flufenamic acid showed improvement in crystal size over prior literature results. Through
the use of a novel simultaneous design and control (SDC) methodology, we have further
optimized the flowrates and crystallizer geometry in tandem.

xxvi
We have further investigated the robustness of this process and observe significant
sensitivity to error in antisolvent flowrate, as well as the kinetic parameters of
crystallization. We have lastly performed a parametric study on the use of the MSMAPFC for in-situ dissolution of fine crystals back into solution. Fine crystals are a known
processing difficulty in drug manufacture, thus motivating the development of a process
that can eliminate them efficiently. Prior results for cooling crystallization indicated this
to be possible. However, our results show little to no dissolution is used after optimizing
the crystallizer, indicating the negative impact of adding pure solvent to the process
(reduced concentration via dilution, and decreased residence time) outweighs the positive
benefits of dissolving fines. The prior results for cooling crystallization did not possess
this coupling between flowrate, residence time, and concentration, thus making fines
dissolution significantly more beneficial for that process. We conclude that the success
observed in hitting the target distribution has more to do with using multiple segments
and having finer control over supersaturation than with the ability to go below solubility.
Our results showed that excessive nucleation still overwhelms the MSMA-PFC for in-situ
fines dissolution when nucleation is too high.

1

CHAPTER 1. INTRODUCTION

1.1

Motivation

In recent years, the continuous production of pharmaceuticals has grown considerably in
research attention. Currently, most pharmaceuticals are produced via batch processes, at
considerable expense and difficulty. A variety of financial [1]–[11] and regulatory [12]
pressures on the pharmaceutical industry has motivated the research into cost-saving,
streamlined approaches to their operations. The “blockbuster drug” business model has
proven financially unsustainable. Drugs can take from 10-15 years to develop, have only
a 20% chance of FDA approval, and cost between $800 million and $1 billion to bring to
market [13]–[15]. Many currently-available, on-patent drugs lack suitable profitgenerating replacements once their predecessors go off-patent, and the drug industry
faces stiff competition from generic manufacturers.

Crystallization is an area of considerable interest from the standpoints of continuous drug
manufactures as well as process systems engineering. While useful for small quantities of
drugs, drugs which require higher production volumes would benefit greatly from
continuous crystallization. As a pure systems problem, crystallization processes are
interesting due to their high nonlinearity.
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These processes demand a different set of mathematical tools to model and optimize
them properly, as well as different solution approaches.

Continuous crystallization systems, while already heavily used in many other industries,
have attracted new interest for application to pharmaceuticals. Current methods of
crystallization are focused overwhelmingly on batch systems. This is problematic, since
batch systems have intrinsic drawbacks related to design, control, and scale-up.
Continuous crystallization systems can be considered a sub-field of the more general
research field of process intensification.

A variety of new crystallizer designs have been proposed that can, via novel flow
chemistry, crystallize drugs with a greater level of precision and control. One particular
type of continuous crystallization is the plug flow crystallizer (PFC), which has been the
subject of several investigations in recent literature (see Table 4 beginning on page 84).
Lakerveld et al. [16] pointed out the need for more investigation into the crystallizer
design itself, and that detailed modeling would be needed for the optimization thereof. A
new design based on the PFC is the multisegment, multi-addition plug flow crystallizer
(MSMA-PFC). This crystallizer is a group of PFCs linked in series, with an independent
supersaturation actuator for each segment. This design allows for greater control of
supersaturation in one dimension versus a stirred tank.

Currently, there is a lack of design and optimization methodology in the literature for
continuous crystallization systems. Multiobjective optimization is a useful tool for fully
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investigating the tradeoffs between possible designs of a system, as well as identifying
the envelope of attainability [17]. Much benefit could be achieved by use of an integrated
framework for the design, optimization, and robustness analysis of new crystallizer
designs, of which the MSMA-PFC is a contemporary example. Such a methodology
would help trim the design space considerably when searching for an optimal design.

The robustness and sensitivity of continuous crystallization systems for pharmaceutical
use has also gone unstudied. The topic of sensitivity in crystallizers has been examined
for the case of batch crystallizers by Ma et al. [18] using a worst-case framework, which
among other conclusions showed that inaccurate control can wipe out the entire benefit of
optimal control. For effective design and operation of new crystallizer technologies, it is
important to know the impact of parametric uncertainty, random disturbances, control
error, and observer uncertainty on quantities of interest (e.g. shift in CSD shape, purity).

1.2

Research Aim and Objectives

The aim of this research is to develop a framework for modelling and optimizing a new
type of antisolvent plug-flow crystallization systems, the MSMA-PFC. To analyze
continuous crystallization system, we borrow the concepts of constrained optimization
from the field of process systems engineering. By use of this modelling and optimization
framework, we can investigate the capabilities of the system for achieving desirable
properties of the generated crystals. Such a framework can gauge the feasibility of a plug-
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flow crystallization system for producing high-quality crystals of a particular drug, given
correct experimental parameters. It can also predict correct operating conditions and
vessel designs that will produce crystals with desired properties. We summarize our aims
as:
a. To gain a broad view of the impact of continuous crystallization’s potential via a
thorough literature review of the continuous drug manufacturing research field.
b. To develop a model-based simulation framework for modelling the plug-flow
crystallization process.
c. Unite the simulation framework with a multiobjective optimization methodology
in order to investigate possible control strategies. This combined simulationoptimization based framework is used throughout this work as a method of
optimizing the properties of crystals at the exit of the crystallizer.
d. As an example of this framework in action, analyze the performance of a new
type of plug-flow crystallizer, termed the multi-segment, multi-addition plug-flow
crystallizer (MSMA-PFC). This apparatus consists of a group of PFC’s linked in
parallel, each with independent supersaturation control. To demonstrate this
framework in action, our chosen crystal properties have been the size and spread
of the crystal size distribution – though the framework is extendable to other
important quality measures such as polymorph content or aspect ratio.
e. Examine the sensitivity of the crystallization process, and determine the how this
sensitivity affects the design considerations for design and control.
f. To create a simultaneous design and control methodology which optimizes over
not only flowrates but the actual crystallizer geometry as well.
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g. To investigate the feasibility of plug-flow antisolvent crystallization for
eliminating undesirable small crystals (“fines”).
1.3

Research Contributions

The main contributions of this thesis are summarized as:
a. This thesis surveys not only the continuous crystallization literature, but the
continuous pharmaceutical manufacturing field holistically. By overviewing the
research field in this manner, it becomes more apparent how our contributions fit
into the greater network of ideas and concepts.
b. Through use of a population balance model-based framework, we have developed
a model for the MSMA-PFC, coupled with the mass balance equation, which can
track the properties of drug crystals at the exit of the crystallizer. This model
incorporates the effects of dilution and also dissolution.
c. Demonstrated that the optimization of a multi-segment plug-flow crystallizer is a
nonconvex problem.
d. Used multi-objective optimization (aided by the genetic algorithm) to investigate
the envelope of performance of the crystallizer, and compared obtained values
with prior literature results. Our results compare favorably (e.g. larger crystals).
This methodology was able to successfully surmount the observed nonconvexity
of the MSMA-PFC optimization problem.
e. Investigated the sensitivity and robustness of the MSMA-PFC with respect to
uncertainty in important values such as flowrate and kinetic rate parameters.
Using a Monte-Carlo method, we determined that error in flowrate significantly
affects the performance of the MSMA-PFC. Also, we found that significant
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coupling exists between errors in crystallizer inputs, which significantly impacts
the design and operation of the crystallizer.
f. Through use of a simultaneous design and control (SDC) methodology, we
successfully optimized not only the individual flowrates in the MSMA-PFC, but
the geometry of the crystallizer as well. Significant improvement is shown when
using SDC versus optimizing flowrates alone on a static geometry.
g. Demonstrated that the dissolution of fine crystals in-situ is a sub-optimal strategy
for the MSMA-PFC class of crystallization problems.

1.4

Thesis Structure

CHAPTER 1 of this thesis gives a broad overview of the remainder of the work. This is
to supply the reader with a “bird’s eye view” of the topics discussed herein.

CHAPTER 2 provides the reader with a literature review. We begin with a discussion of
the current manufacturing process in pharmaceuticals, and discuss various problems and
challenges related to it. New continuous technologies are discussed as well in areas
outside of crystallization. We move then onto the importance of crystallization in the
manufacture of drugs, and how continuous crystallization can solve many current
problems encountered with batch crystallization. The remainder of the chapter is
background information to help the reader understand the work in
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CHAPTER 3 provides a more specific literature review on the topic of continuous
crystallization. We give an overview of many contemporary devices for crystallization. A
table at the end of the chapter neatly summarizes many studies of continuous
crystallization for the reader.

CHAPTER 4 is the first contribution chapter of this work. It presents our results on the
multiobjective optimization of the MSMA-PFC. We further investigate the robustness of
the design with respect to uncertainty in kinetic parameters as well as flowrate.

CHAPTER 5 revisits the system from CHAPTER 4 on the simultaneous design and
control (SDC) problem. In this problem, we optimize the crystallizer not only over the
flow profile, but the vessel geometry as well. Significantly more control over mean size is
shown possible by optimizing both design and control in tandem.

CHAPTER 6 is the final contribution of this work. In this chapter, we have investigated
the use of the MSMA-PFC for in-situ dissolution of fine crystals. Unlike in Chapter 4, the
new MSMA-PFC is capable of going below solubility, thus dissolving fine crystals while
keeping large ones. The results show however, that dissolution is shown to be a suboptimal strategy. Comparison with prior in-situ fines dissolution work is given as well.

CHAPTER 7 is our summary and future directions chapter. In this chapter, we
summarize the results of the previous chapters. We furthermore expound upon new
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technologies and extensions of this work that can be of significant impact in
crystallization design and control.
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CHAPTER 2. LITERATURE REVIEW

2.1

Introduction

We begin with a general overview of the present state of pharmaceutical manufacturing,
which foreshadows the benefits of continuous pharmaceutical manufacturing (CPM)
discussed in section 2.2. The flowchart in Figure 2.1 below gives an overview of a drug
manufacturing process (based on the diagrams in [1], [19]). This flowchart will serve as a
useful guide in the discussion of pharmaceutical manufacturing. Once the basic process
overview behind pharmaceutical manufacturing is presented to the reader, it will be clear
what problems affect the process, and how our work fits in as a solution to some of those
problems.

2.1.1

Synthesis

In Figure 2.1 below, raw materials enter the process at two points. At the start of the
process, raw material precursors are transported to the manufacturing site for use in
synthesis to create that active pharmaceutical ingredient (API). The API is the molecule
which actually provides the curative effect to the patient.
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During this phase of the operation, precursors are reacted together, which usually takes
several reactions and work-up steps to attain the desired molecular form. In certain
instances (e.g. penicillin), a bioreactor or fermenter is used to directly synthesize the API,
followed by a variety of cleaning and filtration steps. Multiple syntheses reduce overall
yield significantly. During this phase, workers may be in contact with toxic amounts of
precursor or final API compounds. The solution containing the API is contaminated with
unreacted compounds and organic solvents, and requires a separation.
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Problems and Challenges

Manufacturing Stage

Feedstock variability
● Sterility
● May be a particle phase
● May be biological

Equipment

●

Raw precursor
input

Incomplete reaction
● Safety issues
● Organic solvents and pollution
● Batch-to-batch variability
●

●
●

API Synthesis

Stirred batch reactor
Fermenter or bioreactor
SYNTHESIS

Control and scale-up difficulties in batch
mode.
● Observation is difficult.
● Batch-to-batch variability.
● Wide uncertainty in experimental kinetic
parameters
● Difficult to observe process.

●

●

Batch crystallization

Crystallization
SEPARATION
Raw excipient
input

●

Mathematically complicated to model.
● Complicated fluid-solid interactions
● Difficult to handle powder phases.
● Difficult to observe process.

Wet granulator
Dry granulator/roller compactor
● Powder blenders
● Hot extrusion
●

Particle
Modification and
Transport

Results from prior processes can affect
hardness, dissolution rate, color, taste,
friability, etc.
● Difficult to achieve uniform thicknesses for
coated tablets.
● Coating process must not affect tablet's
curative properties.

●

●

●
●

Tablet press
Coating pan

Tablet Forming
and Coating
FORMULATION

Figure 2.1 Basic flowchart of a pharmaceutical manufacturing process.

2.1.2

Separation

Observing the middle of Figure 2.1, crystallization is the secondary process in
pharmaceutical manufacture [1], [19]. This section directly relates to this thesis, as we are
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investigating a new type of crystallizer. This new MSMA-PFC design is an intensified
process that alleviates many of the problems described in the crystallization section of
Figure 2.1. Crystallization is a key pre-formulation operation in pharmaceuticals [1], [5],
[20]–[23], and between 80% and 90% of drugs are purified in this way [21], [22], [24].
Crystallization is predominant because it can achieve very high purities (> 98%).
Crystallization also does not require harsh conditions (e.g. distillation), which would
likely destroy most API molecules. Multiple crystallizations may be necessary to achieve
sufficient purity, much in the same way that multiple equilibrium stages are required for
distillation, liquid-liquid extraction, and gas-liquid extraction. Following crystallization,
crystals require filtration, washing, and drying. The performance of the filtration,
washing, and drying processes are highly dependent on the properties of the product
crystals. The performance of downstream formulation processes are also dependent on
crystal properties.

2.1.3

Formulation

“Formulation” is meant the final steps required to convert refined pharmaceutical crystals
and various excipients into a “final dosage form” (FDF). As the name implies, an FDF is
meant to deliver a precisely metered quantity of API to the patient. Besides the quantity
of drug, the dosage form must possess the desired physical and pharmacological
properties that ensure proper bioavailability in the human body. The complexity of the
human body places tight constraints on the properties of the FDF [25]. FDF’s can take on
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many forms, which can dramatically change the formulation process. Examples are too
numerous to list exhaustively, but include oral tablets (hard tablets, lozenges, chewable
tablets for children, sublingual tablets), injectable drugs, topical creams, and inhalants.
Each of these FDF’s has a variety of engineering challenges associated with continuous
manufacturing. Since crystallization often cannot produce crystals with the desired
properties, a variety of particle modification processes are used to remedy this during
formulation. These include agglomeration operations such as wet granulation, rollercompaction, and hot-melt extrusion [26]–[29]. Subsequently, API crystals are blended
with a variety of excipients to attain desired properties (e.g. dissolution rate, color,
sweetness, etc.). Excipients may also be process control agents, such lubricants, which
can enhance qualities such as flowability [29]. Excipients often compose the majority of
the dosage form [30]. Blending of powders together is another challenging process, since
it is difficult to mix powders with consistent homogeneity. Following blending is
typically a granulation process, which turns fine powders into larger chunks. Granulation
is done for a variety of reasons, such as making the powder phase easier to handle, make
tablets easier to press [25], and reducing the respiratory and explosion hazards from dust
clouds [19]. Increasing the level of control over the CSD would simplify much of the
formulation stage. Once powders are sufficiently mixed and/or granulated, they are
pressed under mechanical force to create tablets. The thesis by Cipich on gives a good
overview of several processes involved in continuous tablet production, including
continuous blending, dry granulation via roller compaction, and a continuous tablet press
[29].
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To summarize the pharmaceutical manufacturing process, the operations commonly
found in the pharmaceutical industry are complicated from a scientific and engineering
standpoint. Most operations after the synthesis stage possess at least two phases, such as
crystallization slurries or wet granulation mixes. Analysis, design, scale-up, observation,
and control of these processes is difficult to do. This is further complicated by the batch
nature common to most of these processes, which are not only spatially complex, but
time-dependent as well. Few major improvements to these processes have been attempted.
Our objective in this work is, through the use of a rigorous modeling and optimization
framework, investigate the potential use of the MSMA-PFC for producing
pharmaceutical drugs.

2.1.4

Problems Related to Batch Processes in General

Most pharmaceutical manufacturing operations, such as crystallization, are performed
using inefficient batch processes, and basic understanding of these important unit
operations is limited. This is in contrast to the bulk chemicals, food, and semiconductor
industries which are mostly run continuously in well-understood processes [9], [31].
Manufacturing costs accounts for about 30% of sales for brand-name drug manufacturers
[11], with 30-40% as the general industry average [7], [11]. In addition to being laborintensive and environmentally wasteful, current drug manufacture is error-prone [32],
leading to costly recalls and contamination [7], [9], [15], [19]. The drug industry’s batch
operations are also widely distributed geographically, which requires costly, time-
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consuming transport of material between manufacturing plants [33]. Clearly, complete
manufacturing within a single manufacturing site would be preferable to playing “factory
pinball” with various drug components.

Despite being worth over $250 billion [8], the pharmaceutical industry’s manufacturing
apparatus has become antiquated. Most industries shift to continuous production as
quickly as affordable [13]. This is because, at large economies-of-scale, continuous mode
is more efficient than batch processes. The reader might wonder, “Why the lag in
technology?” The reason for this lag, is that the pharmaceutical industry has historically
been tightly regulated, with even minor changes to processes requiring re-approval [13],
[34]. However, recent reforms [12], [35], [36] to the regulatory framework have greatly
lessened this impediment and given much more freedom to make process changes within
an approved “design space” (see [34]). To address this lag in technology, the
pharmaceutical industry has recently expressed great interest in upgrading and
streamlining its research, development, manufacturing, and logistical operations.

2.1.5

Problems Related to Batch Crystallization

We are especially interested in this work on problems related to batch crystallization, and
how continuous crystallization can solve many of these problems. The continuous
crystallization of pharmaceuticals is a research endeavor with very high potential impact,
as crystallization is a ubiquitous process operation in pharmaceuticals and a key stage at
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which quality can be engineered into the final product. This folds in with the concept of
“QbD”, discussed in section 2.2.1. Most industrial pharmaceutical crystallization is done
batch-wise, which has a variety of drawbacks related to scale-up, observation, and control.
Efficient, controlled production of drug crystals with desired properties has been
described as a “primary bottleneck” to large-scale production of certain drugs [37].
Improving crystallization operations can improve the manufacturing process as a whole,
since the properties of the produced crystals affect the performance of subsequent
processes [21], [38]. Table 1 below summarizes the problems associated with batch
crystallization. Plumb [19] neatly summarizes the problems associated with batch
manufacturing as follows: “Batch processes are poorly understood, time-dependent, and
scale-dependent operations.” This is in contrast to continuous processes, which are
capable of attaining a physically and mathematically well-defined steady-state of
dynamic equilibrium. Batch processes also fail to process all material in a uniform,
consistent fashion, due to the existence of uncontrollable spatial gradients in fluid
velocity, supersaturation, temperature, solids fraction, and chemical composition. This is
in contrast to a steady-state, continuous flow process, over which significant control over
these

gradients

is

possible,

as

well

as

tight

residence

time

distributions.

Continuous

Batch

•

•

•

•

•

•

•
•
•
•

Easier scale-up (depending on exact

setup) due to better mixing and/or heat

transfer.

Easier to control.

environmental

impact

Small equipment size.

disturbance causes problems.

Less

of scale.
if

More cost-effective at larger economies

operate.

Much less fluid hold-up; safer to

environmentally unfriendly.

Entire batch must be discarded in event of disturbance; costly and

Plugging and fouling is a problem.

Observation of system difficult; sensors disturb flow.

Modeling and control methods not well developed.

New technology; requires new capital investment.

required.

If target crystal size distribution is not achieved, milling operations are

•

simple (e.g. a beaker.)

Impeller required to mix fluids; great difficulty in scaling this properly.

•

•

Laboratory versions of equipment are

Safety issues with large volumes of fluid.

Labor-intensive operation.

•

management methods exist.

Attrition and breakage become problems at larger sizes.

Batch-to-batch variability.

Difficult to scale-up.

Cons

•

•

process optimization, and informatics

•

•

control,

Sophisticated

•

modeling,

•

Infrastructure already exists in industry.

•

Pros

Table 1 Tradeoffs between batch and continuous crystallization.
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Scale-up is another serious problem encountered in batch crystallization. In chemical
engineering, a common problem is taking a small, laboratory-scale system, and
increasing its production capacity to meet mass-market demand. For drugs, API
crystallization is almost entirely done batch-wise, and direct scale-up from the laboratory
model is difficult to achieve [39]. The main reason the scale-up of agitated crystallization
vessels is difficult is due to incongruous scaling rules for heat, mass, and momentum
transfer. To scale-up a crystallizer, one calculates a set of dimensionless numbers based
upon the geometry of the crystallizer, the impeller design, fluid properties, and the power
input to the impeller. Dimensional analysis of the governing equations shows that it is
impossible to preserve all dimensionless groups with increasing tank size, regardless of
agitation speed [39], [40]. The phenomena described by these dimensionless numbers –
such as heat transfer rate, hydrodynamic flow patterns, shear rate, and suspension
velocity - scale in opposing ways [40], [41]. Plumb [19] provides numerical results
clearly indicating this problem, and Mersmann and Foster [42] gives a large table of
dimensionless correlations for stirred vessels. Significant changes in the velocity field can
result upon scale-up, resulting in supersaturation gradients and ultimately a CSD that
does not meet desired characteristics [40], [43]. Scale-up also leads to changes in the
internal hydrodynamics of the crystallizer that are difficult to model and predict [39], [44].
These issues are discussed at length by Genck [39], Wei [45], and in the text by Peker
and Helvaci [46]. In continuous crystallization (and CPM in general), we replace largevolume process equipment with smaller apparatus that output lower, constant volumetric
flow rates. Continuous operation requires somewhat more time to accomplish for the

19
same relative amount of material to be processed, but at the gain of superior control over
the product properties.

A workaround for the scale-up problems is to avoid scaling-up the batch apparatus, and
just use a larger number of batch crystallizers in parallel. This however, leads to much
greater capital and operating costs, and the problem of batch-to-batch variability [19],
[24], [47]. This variability results from the fact that even small discrepancies in operating
conditions can drastically change the physical properties of the obtained crystals [21].
There are a variety of causes for this problem, such as differences in feedstocks [21], [30],
[48] (upstream variation), mechanical wear and fouling, and reusing the same vessel for
multiple processes [49]. These changes can alter the hydrodynamic and/or heat and mass
transfer characteristics of the equipment slowly over time, thus altering the CSD obtained
from a particular vessel.

Lastly, despite the simplicity of the equipment, batch crystallizers are highly complicated
nonlinear systems [19], [38], [40], [50], [51], and complex dynamic behavior arises with
increasing complexity of the crystallizer network. Tavare has compiled an expansive
table of dynamic phenomena observed in conventional MSMPR systems, which are
stirred tanks similar to a batch system [51]. Multiplicities of steady-states, oscillations,
orbits, and limit cycles have all been observed [47], [50], [52], and appear generally to be
caused by the recycle of re-dissolved fines. Time-dependence of the CSD is highly
undesirable, since disturbances in the crystallizer can propagate downstream to other
processes, and render the final product’s quality inconsistent [20], [53], [54]. A
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continuous approach solves many of these problems, as continuous processes are not as
difficult to control and scale-up. The analysis of the MSMA-PFC is a step forward
towards the “blue sky” vision of fully continuous, automated drug manufacture by
streamlining a crucial separation step.

To summarize, particulate processes in the drug industry are poorly understood; this goes
for not only crystallizers but also dry-powder-phase processes and liquid-powder
processes. The drug industry is looking to remedy these problems by shifting to the more
economical continuous mode of operation. This motivates our study into new crystallizer
designs, that can produce high-quality crystals consistently with much less severity of
scale-up and much easier mechanisms of control over batch processes.

2.2

Overview of Technologies for Continuous Pharmaceutical Manufacturing

The pharmaceutical industry is modernizing its research, manufacturing, and logistical
operations. The technologies discussed in section 2.1.1 are almost entirely run in batch
mode currently, which is inefficient at the pharmaceutical industry’s economy of scale.
Research effort is increasingly being done toward continuous pharmaceutical
manufacturing (CPM). Several industry-academic partnerships have appeared to develop
technologies along this line, such as the Novartis-MIT Center for Continuous
Manufacturing [23], [55], and the Center for Structured Organic Particulate Systems [9],
[56]. These technologies snap a panorama of the chemical engineering corpus, and are
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highly inter-disciplinary, such as the continuous feeding of powders, continuous
blending, freeze-drying and granulation [9], [28], [29], [31], [57]. The work by Mascia et
al. [23] at the MIT group is a good summary of the benefits possible with continuous
manufacturing. That work discusses a variety of improvements their continuous tablet
plant has made over conventional batch, especially in the reduced number of unit
operations and an 84% reduction in plant residence time. This research has great potential
benefit in reducing manufacturing costs, increasing product quality, and improving
consumer safety. Preliminary estimates of the impact of CPM show cost reductions
between 25%-40% [5], [20], [23], or higher [19]. Equipment efficiencies of 30% are
common today, but continuous processing can attain over 80% efficiency [19].

2.2.1

Quality-by-Design (QbD) Thinking

Variability is a ubiquitous problem in contemporary pharmaceutical processes [19], [48].
Raw material variations in composition can affect the yield of API produced during
chemical reaction, as well as contamination. Variability in excipient properties is a
serious problem as well, [48], [58]. Even though these components contain no API,
excipients are added to alter the physical properties of the final dosage form; especially
the dissolution rate. Variation in particle size distribution, composition, and other
properties of an excipient can lead to off-specification FDFs [48]. The pharmaceutical
industry’s current approach to handling off-specification product is to simply throw the
batch out, which increases costs and environmental impact.
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The variety of possible FDF’s, tight constraints on product quality, high manufacturing
costs, and wide variability in final products has motivated the introduction of Quality-byDesign (QbD) thinking into pharmaceutical process design. Strongly encouraged by the
FDA [35], Quality-by-Design (QbD) is a methodology for reducing product variability
during manufacturing. Through a complete process understanding of inputs, outputs, and
disturbances, and a list of target specifications for the final product, it becomes possible
to “build quality into” the final product [59]. When successfully implemented, product
specifications are very likely to be on-target at the end of the process [34], [60]. Our own
work directly relates to the concept of variability as shown in CHAPTER 4 and
CHAPTER 5, where the mathematical framework we developed was used to directly
attempt to minimize unwanted variability in the crystal product.

2.2.2

Critical Quality Attributes and Critical Process Parameters

Wu et al. [9] discuss the concept of QbD at length in their comparison of chemical
engineering successes and opportunities in the pharmaceutical and semiconductor
industries. QbD involves defining the product fully in terms of critical quality attributes,
or CQA’s. CQA’s are primarily linked to product requirements and safety, but can also
be tied to other important “marketing” type characteristics, such as having the proper
color or shape. Then, the proposed manufacturing process is studied in detail using
models, experiments (especially design-of-experiments, or DOE, approaches [1], [34],
[61]), and other prior knowledge [62], to identify the critical process parameters (CPP)

23
that impart the most variability into the final product. A CPP may also be an important
process disturbance. The collection of process inputs and CPP’s defines the “control
space,” within which we capable of hitting any of the accept CQA’s in the “design space.”
In our work , an example of the CQA would be the size of the produced crystals, while a
CPP would be any of the flowrates. Further discussion of CQAs and CPPs is given by
Bondi and Drennen [34]. The QbD archetype stands in contrast to the traditional method
of Quality-by-Testing (QbT) for pharmaceuticals, where large samples of drug products
are destructively tested at the end of the process, while still failing to test the quality of all
the drug product intended for public release.

2.2.3

The Problem of Quality-by-Testing

Figure 3.1 below demonstrates the inadequacy of Quality-by-Testing. In Figure 2.2, each
colored square represents an allotment of drug that has been randomly selected for
quality-assurance testing. When performing lot testing, the samples taken for analysis are
obviously checked, but their sibling products are not, and are merely assumed to be safe
or dangerous based on the results of sampled ones. In Figure 2.2(a), the random selection
has worked as intended – some of the contaminated samples are discovered, deeming the
lot unsafe. However, in Figure 2.2(b), the random selection has chosen solely onspecification samples, but several contaminated ones evade detection. Bear in mind, that
all of the samples in Figure 2.2(a) would be rejected – not just the two off-specification
samples identified. This problem neatly demonstrates the goal of QbD – to eliminate the
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need for off-line testing by tightly controlling all variability in the process, with
continuous monitoring and logging of all product properties from entrance-to-exit. In this
manner, the entirety of the released drug product is tested and guaranteed to be safe, at far
lower cost than using repeated off-line testing. Currently, testing is done a priori using
analytical techniques such as near-infrared spectroscopy [48] and nuclear magneticresonance spectroscopy [30]. However, since feedstocks are usually natural products [30],
there are many potential sources of variability [58], and it is impossible to eliminate them
all. Given measurements of feedstock properties, it can be difficult to know what process
adjustments should be made to achieve a consistent final dosage form. The correction of
this variability by advanced process control strategies and novel process designs are some
of the major thrusts of research in continuous pharmaceutical manufacturing.

(a)

(b)

Figure 2.2 (a) Depiction of pharmaceutical lot testing. Blue samples are safe, but brown
ones are off-specification.
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2.2.4

QbD and Crystallization

Crystallization is a key operation in drug manufacture. In crystallization, one typically
desires large crystals with little size variance – or more generally, desires a certain CSD.
As we have mentioned previously, crystallization is typically near the beginning to the
middle of the flowsheet. There is significant interaction between the CSD obtained
during crystallization, and the efficiency of other downstream process operations. Proper
development of crystallization processes can provide much greater control over these
important properties earlier in the process, making downstream processing much easier –
or eliminating certain unit operations altogether. At the same time, it can also greatly
improve the drug’s final quality. Batch crystallizers, as discussed in section 2.1.4 have
serious shortcomings in the way of scale-up, monitoring, control, and product consistency,
making it difficult to apply QbD to the full drug manufacturing process. This motivates
the development of more novel crystallization technologies, with better control over
crystal quality and more economical scale-up [21]. To summarize, proper control of
crystallization processes is necessary for quality to be designed into the drug product.

2.2.5

Process Analytical Technology

Process analytical technology (PAT) encompasses a variety of advanced mathematical
tools, data management methodologies, and chemical analysis equipment that aid in the
production of safe, cost-effective drugs via improved process observation [36]. One
might consider PAT to be the evidence-based analog of drug manufacturing, compared to
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“evidence-based medicine” in the practice of medicine [34], [63]. Bondi and Drennen
[34] bring up the simple but astute point that, unlike virtually every other product a
consumer might use in his daily life, he has no idea whether the medicine he is using is
working or not. It is critical that drugs released to the public not only be safe, but actually
work as intended using proven scientific methods. This is hardly the case with the drug
industry today, which relies heavily on end-product testing and strict adherence to master
recipes as a means of quality assurance [32]. We discuss several definitions which will be
of benefit to the reader. From Yu et al. [64]:
•

In-line: Real-time measurement of the process material as it is being processed. This
is the ideal method of observing a CPM process.

•

On-line: Process material must be diverted to analysis equipment, but is still
monitored during the process.

•

At-line/Offline: Process material must be taken elsewhere for analysis. This is the
standard manner in which pharmaceuticals are tested. At-line refers to analysis at the
manufacturing site, offline is elsewhere. Both are undesirable, as they are slow,
expensive, and a risk factor for process contamination.

•

Invasive: An observation probe must be in contact with the process for a reading to
occur. This situation is unfavorable for obvious safety and health reasons. There are
also problems associated with fouling of the sensor, chemical attack, and laborious
cleaning and sterilization processes.

•

Non-Invasive: No probe is necessary. A reading can be obtained without any contact
with the process material.
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The Venn diagram in Figure 2.3 illustrates which of these qualities belongs to various
types of analytical chemistry tools. Monitoring of pharmaceutical and crystallization
processes is generally difficult, and significant technical challenges exist in practical
implementation of these apparatus for adoption by industry. Non-invasive process
analytical technology (PAT) sensors are highly favored by regulators and industry, since
there is less direct contact with the process material. The Venn diagram in Figure 2.3
below shows the relationship between the previous categories and the current
technologies in use [13], [64]–[71]. Clearly, there is a dearth of noninvasive sensors. The
extensive table in Scott and Wilcock mentions virtually every process involved in drug
manufacture except crystallization [32]. Process analyzers for pharmaceutical
manufacturing are an active field of research, and crystallization is not the only subfield
of CPM where new sensors are being developed. Gradinarsky et al. investigated the user
of a coaxial microwave probe sensor for the measurement of moisture content in a wet
granulator [72]. The use of new PAT sensors for the monitoring of chemical reactions,
granulation, and freeze-drying have been reviewed extensively by Scott and Wilcock [32].
Concentration (more generally, supersaturation) is a critical variable in for monitoring in
crystallization processes, since nucleation and growth are direct, strong functions of the
supersaturation [37]. Sensors such as FTIR [37] and Raman spectroscopy can feasibly
measure concentration. FTIR is also suitable for simultaneous measurement of multiple
concentrations in a multi-component mixture. Raman spectroscopy is particularly
attractive, due to the non-invasive nature of the instrument. Particle vision measurement
is probably the most intuitive to understand of all the analytical techniques discussed here
– essentially, the technique is simply taking pictures of the crystals, and visually
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computing sizes and shapes. However, the image analysis algorithms used to accomplish
this physically are complicated. Furthermore, very high solids concentrations will make
image analysis impossible, since it will become impossible to differentiate individual
crystals.

Acoustic
emission
spectroscopy

CSD

Coulter
counter

FBRM

Particle
vision

Particle
vision

Crystal Shape

Enantiomeric Form

Refractometry

Ultrasound wave
attenuation

X-ray
diffraction

Near infrared

Invasive

ATR-FTIR

Figure 2.3 Venn diagram of critical process parameters of interest for measurement. As can be readily seen, the overwhelming
majority of sensors are invasive.
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2.2.6

Real-Time Monitoring and Real-Time Release

Real-time PAT monitoring and control abrogates the need for costly post-hoc rejection
testing, and makes feasible the concept of real-time release (RTR), e.g. where the drug is
ready to be packaged and distributed as quickly as it is manufactured, with its quality
assured [73]. Implementation of PAT for real-time monitoring, feedback control of CPPs
(e.g. concentration, purity, temperature, etc.) would permit adjustments within the design
space as necessary to keep the product on-spec [13]. This would be a boon to the drug
industry, which currently requires about 95 days to turn input raw materials into a final
dosage form [32]. RTR also has the significant advantage over batch testing, since the
entire drug product being sold has actually been inspected. As reported in Scott and
Wilcock, to obtain similar levels of quality assurance with rejection testing would
increase the cost of drugs by about 20% [32].

Besides inspecting the entire drug production run, online monitoring also has the
potential to do a better job. This is because end-product testing can only detect serious
deviations from normal quality and high contamination. Furthermore, end-product testing
can only detect bacteriological contaminants that will grow in available biological media
reasonably quickly. Online sensor monitoring using PAT tools (e.g. spectroscopy) would
be significantly more sensitive to contamination or disturbances than end-product testing.
A challenge in crystallization, is the development of sensors that can function without
causing contamination, and can operate correctly despite the presence of a liquid and
dispersed solid phase.
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2.2.7

Multivariate Statistical Methodologies

The complex nature of pharmaceutical manufacturing and crystallization in particular,
sometimes make first-principles modeling very difficult, or outright infeasible. In such
situation, multivariable statistical “black box” modeling methods can be helpful. Such
methods do not seek to match inputs to outputs from a contrived model, but only to find a
model that does match by use of experimental data. Techniques such as partial least
squares (PLS) and principal component analysis (PCA) can use ostensibly unrelated
measurement data to infer and predict system properties [59], [71]. PCA and PLS are
useful tools as well for “data-reduction”, which is very helpful when dealing with the
“data avalanche” typical of CPM processes [13], [74]. Such tools have been used for
some time the field of chemometrics [13]. As shown in Bondi and Drennen, methods
such as principal component analysis (PCA) can be useful quality assurance parameters,
capturing the effect of many variables into a single number, whose deviation from a
certain value is a red-flag that something is amiss [34]. The solution of overdetermined
systems of equations and redundant measurements can be used to create “soft sensors”,
which are not actual hardware sensors, but instead are a mathematically-sophisticated
state observer [71], [75]. Soft sensors can reconcile large amounts of measurement data
with the governing equations to infer an optimal estimate of the true value of the data (e.g.
the Kalman filter [75]). By utilizing multiple measurements of completely different
natural phenomenon, a more accurate state estimate can be obtained. We cover only
small portion of the “CPM-metrics” field here, as the body of literature is extensive.
Other methods, such as design-of-experiments (DOE), response surfaces, and Bayesian
statistics are discussed elsewhere in the literature [59]. A major challenge in modeling of
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crystallization processes is in accurate estimation of their kinetic parameters. Wong et al.
[76] have used an artificial neural network to model the crystallization kinetics of lactose,
including the agglomeration effect. Using first principles to develop a model including
the effect of stirrer speed would have been very difficult. Wu et al. [77] used a full
factorial design (33) and a combination of linear regression models and a neural network
to investigate and model the co-precipitation of naproxen (Aleve™) and Eudragit™.
Other works have focused on dimensional reduction, which is a very powerful method for
simplifying the data analysis, control, and fault diagnosis [59], [78], [79] of experiments
involving CPM processes. Tomba et al. applied a multivariate statistical framework for
organizing and analyzing data from a granulation and tabletting process [59]. PCA was
used extensively in that work to identify dominant variables amongst a large possible set,
in order to properly identify critical process parameters. Routinely a space of 10 or more
variables could be described with only 2 or 3 principal components. Such an approach
can be highly useful in CPM processes. The thesis by Cipich discusses the use of several
multivariate tools for the detection of systematic (“gross”) errors in a continuous tablet
pressing process [29]. In that work, several statistical tests are used for fault detection,
and a quadratic programming problem is solved to reconcile the process measurements.

2.2.8

Technologies for Powders, Particles, and Tablets

While this work is focused mainly on crystallization, it is important for the reader to have
an understanding of the CPM field as a whole. Over 80% of drug FDFs are oral tablets,
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which are manufactured by blending API with powder-phase excipients and pressing
them [29], [80]. Proper control over crystal properties is necessary to achieve a good
press. Oral tablet FDF’s have a variety of manufacturing difficulties caused by the
complicated interactions within multicomponent powder mixtures. Powders possess
properties significantly different from the bulk phase. Particle modification processes are
often necessary to ease handling, such as wet or dry granulation. Such powder systems
are difficult to mathematically model, and cannot be realistically modeled as fluids.
Kleinbudde [28], Vervaet and Ramon [31], and Pernenkil and Cooney [57] have
reviewed the processing of pharmaceutical powders in depth. A vast amount of research
has been done on process design, modeling, and simulation of pharmaceutical powder
processes. We present a brief summary of the research on solid pharmaceutical
processing in Table 2 below. Boukouvala et al. [81] modeled and simulated continuous
blending processes for the homogenization of two-powder mixtures. Four-dimensional
population balance models have been used to track the distributions of size, composition,
liquid content, and porosity of particles within a wet granulator [25]. The discrete
element method has been used to examine the variability in film properties of liquidcoated tablets in rotary coating equipment [82]–[84]. Sinha et al. used finite element
methods borrowed from the field of soil mechanics to investigate the compaction of
powders during tablet pressing [85].

Wet granulation

Coating of tablets

Four-dimensional population balance model

Discrete element method

Fault detection and exceptional events
granulation

Tablet pressing and dry

process in a die

Modeling the tablet compaction

powders

method simulation

Finite element method

Continuous blending of dry

Population balance model, discrete element

Table 2 Summary of pharmaceutical solids processing technologies.
Technology(ies)
Applied Towards

Cipich [29], Hamdan [80]

Sinha et al. [85]

Wassgren, Freireich et al. [82]–[84]

Kalbag and Wassgren, Freireich and

Barrasso and Ramachandran [25]

Boukouvala et al. [81]

Reference
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Figure 2.4 Conceptual diagram of CPM implementing PAT for real-time release of final
drug products. Information collected from analytical chemistry equipment (among other
things) provides evidence of safety and quality.

Pharmaceutical informatics is the application of management information systems (MIS)
tools to the observation and improvement of pharmaceutical manufacturing processes and
quality control [13], [32]. Figure 2.4 above illustrates how the large amounts of data that
can be collected from monitoring tools are another route for implementing QbD and
continuous improvement. Informatics and data mining methods are useful for finding
unforeseen process defects and rapid fault correction [86]. The enormous amounts of data
produced and demanded by the pharmaceutical supply chain forms a complicated data
management problem. Venkatasubramanian [74], [87] and Zhao [88] discuss
pharmaceutical informatics in greater detail. Further discussion of information
management/big-data analytics applied to pharmaceutical manufacturing is beyond the
scope of this work.
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2.2.10 Process Control
The last major topic for review is a discussion of the optimization and process control of
CPM processes, in which continuous crystallization is utilized. In the manufacture of
chemical products, a proper control system is vital for ensuring process stability and
safety. This is especially true in the drug industry, since not only plant personnel but the
customer depend on the proper operation of controllers. For smaller-scale processes,
separate control loops for each unit operation provide a simple method for controlling the
entire process. However, for much larger plants and production levels, the number of
control loops can reach into the thousands, and there can be a significant amount of
detrimental interaction between different unit ops. The optimal control strategy for the
process as a whole will be much different (and significantly more efficient) than a
strategy that is optimal unit-op-by-unit-op. Model-based control of batch and continuous
crystallizers is reviewed in [86], [89]–[91]. This problem of plant-wide control (PWC),
refers to the choices of controlled variables, manipulated variables, what measurements
will be made, and what types of controllers will be used [92]. It is a problem of immense
difficulty and practical importance, and its difficulty is compounded by the presence of
disturbances and uncertainty in process parameters, as well as the fact that the optimal
control structure can shift with time due to market conditions [92], an issue of great
importance to the pharmaceutical industry. Plant-wide optimization and plant-wide
control has been applied extensively in other areas of the chemicals industry. Challenges
arise in the full optimization of CPM flowsheets, due to the complexity of the models
used to describe underlying physical phenomena. Among other methods, an optimization
approach can be applied to PWC, by sifting through possible control structures in some
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fashion, simulating the plant with the generated structure and assumed disturbances, and
then calculating a scoring function based upon the observed dynamic and steady-state
performance (typically profit maximization.) In general, this is a difficult constrained
combinatorial optimization problem (generally, a mixed-integer nonlinear programming
problem, or MINLP), requiring a great deal of computing power to iteratively simulate
the plant. CPM processes are especially difficult to rigorously optimize due to model
complexity. There are a variety of computational difficulties related to fast and accurate
solution of the model equations involved. In addition to solving the mass and energy
balance equations for the plant, the population balance equations must also be solved for
relevant unit operation. Powder processing operations, such as granulation, blending, and
tablet coating, require costly discrete element method (DEM) simulations to model
correctly, as mentioned in section 2.2.8. This problem stymies the use of rigorous
optimization for solving the plantwide-control problem for CPM processes [91]–[93].

2.2.11 Specific Examples of Plantwide Simulation, Control, and Optimization
A review of various plant-wide control methodologies is given by Vasudevan and
Rangaiah [93]. In that work, one can observe a variety of industrial chemical processes
for which PWC has been applied; none of these are pharmaceutical processes. Clearly,
there is a limited amount of literature available on the subject. However, an important
result from the literature studies discussed here is that parameters upstream from the
process can have a significant impact on the quality of the final drug product. Mascia et
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al. utilized a two-layer approach to control system design for their continuous tablet
manufacturing pilot plant [23]. One layer was used for stabilization, whilst the other was
for controlling quality. The stabilization loop kept each unit operation within its specified
bounds, while the quality controller focused on guiding the process to ensure the
produced tablets met quality standards. They present data that demonstrate process
resilience against disturbances. Lakerveld et al. examined the use of optimal average
level control to control disturbances in a buffer tank downstream from a crystallizer and
upstream from a chemical reactor. The exit concentration and outlet flowrate of the buffer
tank was used to stop the propagation of disturbances from affecting the downstream
reactor. The overall work shows robustness is an important requirement for effective
control of a pharmaceutical process. Sen et al. [53] reported results for modeling and
simulation of a continuous pharmaceutical process. The process consisted of a continuous
cooling crystallizer, filter, fluid-bed dryer, and screw blender process for production a
final drug product. Using a dynamic PBM-DEM (population balance model-discrete
element method) model, they investigated the effect of various parameters on the
homogeneity of the API-excipient mixture produced by the blender. As expected, altering
the cooling profile of the crystallizer changes the output crystal CSD. However, the
different CSDs obtained showed a different dynamic response in the API content of the
blended drug formulation, with some profiles being more sluggish than others to reach
the desired final value. Suggested in their study, optimization of the cooling profile could
produce a faster result in the blending process, decreasing the amount of wasted product.
Benyahia et al. [20] performed a much larger dynamic flowsheet simulation. A CPM
pilot plant was simulated using a sophisticated dynamic model, totaling 104 differential
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equations and 2 × 103 algebraic equations. The simulated plant produced drugs directly
from scratch; taking in raw reactant material at the entrance, and producing coated tablets
at the exit. The effect of changing raw material, excipient, and equipment parameters
upon the final product purity was experimented with via simulation. Impurities emanating
from the first reactor in their flowsheet were found to have a significant impact on the
performance of the entire process. Ward et al. [91] have developed a plant-wide control
approach for a combined process consisting of reaction in a CSTR, MSMPR
crystallization, and then filtration with liquid recycle back to the CSTR. While not
explicitly applied to pharmaceutical processes, the scenario is general enough to warrant
discussion here. Despite being able to find well-performing control structures for the
process, some would require real-time monitoring of CSD (or average size) as well as
supersaturation, with no measurement error or time delay. While various monitoring
setups have been demonstrated in the literature for measuring supersaturation and CSD,
this is generally not the case in industry. Finally, a different problem was solved
altogether by Levis and Papageorgeiou [33]. In that work, the investigators formulated a
large mixed-integer linear programming (MILP) problem for large-scale optimization of
an entire pharmaceutical enterprise. The problem was to optimize over a choice of
possible products, how the geographically-distributed manufacturing network would be
set up, what sales goals would need to be met, and how much inventory to hold on hand,
subject to a large number of constraints, for a time span of 13 years (3 years of clinical
trials, 10 years of profitability). This work demonstrates the combinatorial nature of
decision-making pharmaceutical manufacturing management. It is interesting to note that
the time required to scale-up a process is explicitly incorporated into the problem
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formulation. The work also demonstrates how much the geographical distribution of
operations complicates decision-making in the drug industry, and suggests how much
easier it would be if drugs could be processed entirely in a single location.

2.2.12 Uses of Simulation
As mentioned previously, an important issue in the design of CPM processes is
understanding how different unit operations interact with each other, either regarding the
change in location of the steady-state with various parameters, or transient interactions in
their dynamics. Simulation is of great usage in the study of chemical processing plants.
Related to pharmaceutical manufacture, even slight variations in an upstream process (or
more likely, a feedstock), could propagate in a highly counter-intuitive fashion
downstream, rendering the final drug product ineffective or unsafe. Dynamic models
permit analysis of transient responses, allowing one to see how long the process requires
to reach steady state [1]. This is especially important in drug manufacture, as API is often
expensive to waste, and precise quality is required [5]. Programs such as gPROMS and
PARSIVAL have been used in the literature for such simulation work, along with
custom-written programs [53], [94]. In this work, we have opted to write our own
software in MATLAB for simulating and optimizing the crystallization process.

To summarize our thoughts on continuous pharmaceutical manufacturing (CPM), a
variety of technologies are being researched in this field. By using process systems
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engineering concepts for planning the process combined with real-time monitoring and
control, variability in the final product can be greatly reduced or eliminated altogether.
Quality-by-Design (QbD) is a manner of designing the process as such that all variability
is minimized, eliminated, monitored, and controlled. Batch crystallization is a barrier to
implementation of QbD, since batch processes impart uncontrollable variability into the
final product. A variety of new analytical sensors are being designed in order to enabled
noninvasive, continuous on-line and in-line process monitoring. Multivariate statistical
methodologies are also being applied as “soft sensors”, where knowledge of model
equations and a known set of observations can be used to refine the current state estimate.
Population balances, finite element methods, and discrete element methods have been
applied to the difficult matter of modeling solids processing operations, such as wet/dry
granulation, tablet pressing, tablet coating, and of course, crystallization. Plant-wide
control and multi-unit modeling and optimization have been applied to pharmaceutical
processes.

2.3

The Basic Science of Crystallization

Crystallization can affect important physical properties of drug products, such as
enantiomeric excess, polymorphic composition, and CSD (see Shekunov and York [21]).
These variables are directly related to either the dissolution rate, or in the case of
enantiomeric excess, whether the drug is therapeutic or outright toxic. Table 3 below
discusses the type of impact that crystallization can have on the final drug properties, as
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well as the current degree of control capability. The table also shows how certain
properties may impact the process heavily, but not the curative properties of the drug, and
vice versa. This is especially true of enantiomeric form, which has virtually no impact on
the process, but can mean the difference between producing an effective drug or a deadly
toxin.

A short tutorial on crystallization can be found in [38], and the review article by Chen [24]
discusses matters specific to pharmaceuticals. Work by Jones [40] and Tavare [51] focus
more on engineering aspects. The science of crystallization is discussed at length in the
review article by Dirksen and Ring [95], as well as books by Desiraju et al. [96] and
Davey and Garside [97]. The basic principle behind crystallization is to alter the ambient
conditions of the liquid solution (such as by cooling, evaporation, or drowning out) so as
to create a solution which is holding more solute than the solubility limit would prescribe.
Such a liquid is known as a supersaturated solution, and supersaturation is the driving
force for the nucleation and growth of crystals. Figure 2.5 below depicts the solubility
curves for antisolvent and cooling crystallization. Before discussion antisolvent and
cooling crystallization in detail, we make general remarks true about any solubility phase
diagram.

Crystal shape

Purity

Amorphous
character

• Wrong enantiomeric form can either
be non-curative, or harmful to the
patient.
• Dissolution rate increases with
increasing amorphous character.
• Affects shelf-life stability.
• Safety and curative properties of
drug.

• Not much impact - unless conflated
with a different polymorphic form.

Polymorphic
form

Enantiomeric
form

• Effect is conflated with crystal shape.
• Affects hygroscopicity.

• Dissolution kinetics.
• Solubility.
• Bioavailability.
• Shelf-life stability of drug.

CSD shape

Poor
Difficult for very low
impurity levels

• Generally, small purity deviations will
cause little impact.

Varies

Poor

Poor

Moderately good

Controllability

• Amorphous form is unstable; may be
difficult to manufacture.

• Needles cause filtering problems.
• Affects suspension rheology.
• Affects flowability and bulk density.
• Virtually none. Enantiomeric crystals
are, by definition, mirror images of each
other.

• Shape affects tableting strength.
• Fines more difficult to separate.
• Affects washing and drying processes.
• Affects flowability.

• Dissolution kinetics.
• For multivariate CSD, becomes
conflated with crystal shape.

Table 3 The impact of crystallization on important drug properties, and the current capability of control.
Property
Biological Impact
Process Impact
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Figure 2.5 Antisolvent addition and cooling crystallization methods, and illustration of
the solubility curve. The metastable zone is the supersaturation limit at which primary
nucleation occurs. The black points are supersaturated solutions, and the gray points are
undersaturated.

•

Below the solubility curve, dissolution occurs. The solution is undersaturated.

•

On the curve, the crystals are in equilibrium with the liquid phase. The liquid phase is
said to be saturated.

•

Above the solubility curve lies the metastable zone, where crystal nucleation and
growth occur. Here the liquid phase is said to be supersaturated, and the distance
above the solubility curve is known as the supersaturation. Nucleation occurs here
after a period of time known as the induction time.
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•

Above the metastable region lies the limit of the metastable zone (also known as the
labile region). In this region, nucleation is triggered immediately.

Supersaturations above the metastable boundary can result in amorphous solids and oils
[43]. While gas-phase crystallization is possible, industrial practice is typically confined
to a liquid phase, especially concerning pharmaceuticals [98]. Crystals are produced by
creating a supersaturation ( ) within the API solution. A variety of phenomena can be
employed to create a supersaturation. Here we introduce the two most-common methods
of crystallization: antisolvent and cooling.

2.3.1

Antisolvent Crystallization

Antisolvent crystallization (left in Figure 2.5) is performed by adding a second liquid to a
saturated solution in which the solute is much less soluble. Addition of this this second
liquid, termed the antisolvent (also termed the co-solvent or diluent), gradually reduces
the solubility of the mixture, generating a supersaturation. Manipulation of pH can also
work in this fashion [99]. The ordinate of this solubility curve is the solute concentration,
and the abscissa is usually either the mass fraction or volume fraction of antisolvent in
the mixture. The upper and lower bounds on possible antisolvent mass fractions, of
course, are @+A = 0 to @+A = 1.
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2.3.2

Cooling Crystallization

Cooling crystallization (right in Figure 2.5) exploits the temperature-dependence of
solubility. In this method, a saturated hot solution is rapidly cooled, which decreases
solubility, and hence generates a supersaturation. The lower and upper bounds on
temperature are the freezing point of the solution ( $"##)# ), and the decomposition

temperature of the API molecules ( $%#&'( ). If $%#&'( is very low, then cooling

crystallization becomes impractical, which motivates the use of the antisolvent method.
While the discussion of additives and impurities is beyond the scope of this work, it is
worth mentioning that solubility curves can be sensitive to impurities even down to the
ppm level [40]. We also note that cooling and antisolvent crystallization can be done
simultaneously.

2.3.3

Other Methods

Antisolvent, cooling, and vacuum crystallization represent the overwhelming majority of
industrial crystallization methods in practice, but there are some more rare methods used
or encountered in nature. An arcane example is high pressure crystallization. This method
has been used specifically for the separation of mixtures of cresols by using high
pressures to manipulate the melting points of the individual cresol species in the mixture
[51], [100]. Evaporation is another crystallization method. Under moderate heating, the
liquid phase can be driven off by evaporation, which causes a rise in solute concentration
due to loss of liquid volume. An evaporative salt pond is an example of such a

47
“crystallizer.” A combination of evaporation and cooling can be done in tandem with
vacuum crystallization, which applies suction to the system to more rapidly remove
vaporized solvent. A much rarer example is reverse osmosis. Reverse osmosis can also be
used to generate a supersaturation by the expulsion of the solvent across a semipermeable
membrane. While almost never used for practical crystallizations, reverse osmosis
crystallization is known to precipitate kidney stones and gallstones in the human body
[51]. More recently discovered methods of generating supersaturation utilize bubbles
from dissolved gases, electric fields, and lasers. Rungsimanon reports the use of focused
lasers to crystallize γ-glycine, with subsequent dissolution upon deactivation of the laser
[101], [102]. Similar results are reported by Yuyama for L-phenylalanine [103]. The
references in Llinas and Goodman [99] discuss laser nucleation in greater depth. Aber et
al. report the use of strong electric fields to trigger nucleation of γ-glycine in aqueous
solution [104]. Knott et al. report a variety of results related to their work on triggering
crystal nucleation of aqueous glycine by shaking dissolved argon gas bubbles out of the
solution [105]. Ultrasound-induced crystallization [99]. While the mechanism is still
unknown, it is conjectured that the collapse of cavitation bubbles causes a large local
increase in temperature. This creates a great increase solubility, followed by subsequent
cooling from contact with the bulk solution, generating a large supersaturation. Narducci
et al. [106] have experimented the use of ultrasonic waves for shape control of adipic acid
particles. In both continuous and batch mode, smaller, rougher, spherical crystals were
produced than other methods – such as wet milling. The authors suggest improved
mixing from the ultrasound as the mechanism for the shape changes.

48
2.4

Kinetic Processes in Crystallization

Figure 2.6 Basic kinetic phenomena in crystallization processes.

An understanding of the basic kinetic processes is essential to understanding
crystallization. The diagram in Figure 2.6 above summarizes the important kinetic
phenomena in crystallization processes. More detailed discussion of crystallization
kinetics can be found in [97], [107]–[109]. Supersaturation provides the driving force for
nucleation and growth; the greater the supersaturation, the higher the rates of nucleation
and growth. Supersaturation is some measure of the quantity

in Figure 2.5. However,

supersaturation goes by a variety of monikers. The most commonly encountered
measures of supersaturation encountered in the literature are:
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Supersaturation difference, or commonly “the supersaturation” is given by:
∆ =  − 

(2.1)

Where  is the solute concentration (kg/m3 or kg/kg solution), and  is the solubility
concentration (the dark curve in Figure 2.5).
The dimensionless “supersaturation ratio”:
= /

(2.2)

Or lastly the “relative supersaturation”
"#

= ( −  )/

(2.3)

As we shall see in the further sections, greater supersaturation leads to faster rates of
nucleation and growth.

2.4.1

Nucleation

Nucleation is a fundamental process in crystallization. In nucleation, new crystals are
formed due to a supersaturation. Nucleation can occur in a variety of ways, such as
primary, homogeneous, hetereogeneous, and secondary modes. The exact mechanisms
for growth and nucleation are currently not well understood [24], [47]. The most common
theory is that of nuclei or classical nucleation theory. Upon reaching a certain critical
radius, incipient crystals (termed “embryos”) no longer dissolve back into solution, but
continue to grow and form a crystal lattice. Nucleation rate increases not only with the
supersaturation, but the absolute solubility as well. This is due to the fact that the rate of
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cluster formation depends on the probability of solute molecule collisions, which increase
monotonically with increasing solubility. Hence, a lower supersaturation is required to
achieve a given nucleation rate at a higher solubility [110]. Furthermore, nucleation rate
is dependent on liquid viscosity, since greater viscosities impart greater diffusional
resistance from solute particles interacting with a cluster [110].

Primary nucleation is any nucleation process in which no crystals are initially present. In
any supersaturated solution is a large collection of liquid-phase molecular arrangements
with the potential to become crystals, termed embryos. The transition from embryo to
crystal requires passage over a free energy barrier. The energy barrier to crystal formation
is formed by two opposing thermodynamic processes. First is the unfavorable process of
increasing the surface area of a new phase (e.g. the crystal). Secondly is the favorable
process of a solute molecule transitioning from the liquid phase and integrating into a
new solid phase. Once an embryo reaches a critical radius, c& , the free energy barrier
rolls downhill. Once this occurs, crystal formation becomes spontaneous, and a new
crystal pops into existence. The theory of primary nucleation is explained in more detail
elsewhere ([40], [97], [109], [111]).

Homogeneous nucleation occurs when crystals nucleate directly within the bulk phase of
the solution, away from interfaces such as vessel walls and suspended impurities.
Homogeneous nucleation is only achievable under highly contrived experimental
conditions, and is almost never observed in nature. It also requires very high
supersaturation levels to observe, showing that the barrier to homogeneous nucleation is
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large. Small droplets dispersed within a two-phase immiscible flow are one such way to
experimentally observe homogeneous nucleation [110]. Large volumes ( > 100 µl [110])
are typically incapable of homogeneous nucleation, since impurity contamination is too
difficult to control.

More commonly encountered is heterogeneous nucleation, where nuclei form on external
surfaces in contact with the liquid phase. Foreign particles and vessel walls are typical
nucleation sites. When no seeds are present in the solution, no extra surfaces are available
for nucleation. This leads to a nucleation law of the form:
 = 89

9

(2.4)

Where  is the nucleation rate (#/m3∙s), 89 is the nucleation rate constant (#/m3∙s),

is

the supersaturation ratio (dimensionless), and S is the nucleation order (dimensionless).
Any of the other definitions of supersaturation described in section 2.4 are also valid with
(2.4).

When crystals are already present in the system (a “seeded” solution), the extant crystals
provide extra sources of nucleation. During secondary nucleation, the extra surface area
provided by the extant crystals possesses more nucleation sites than the solution by itself.
Furthermore, processes such as shear-induced crystallization and crystal-crystal contact
can trigger additional nucleation as well. The number of nucleation sites scales upward
with the content of crystals in the slurry, and thus expressions for secondary nucleation
include an intensive quantity term for total crystal content. This leads to secondary
nucleation, with a rate law of the form:
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 = 89 GI

(2.5)

Where GI is the 8 J moment of the crystal size distribution. Often, ≈ 1, and 8 = 2 or 3.
The moments are directly related to the quantity of crystals in the solution, so this
expression intuitively makes sense (see [111] for a discussion of crystal moments). The
more crystals there are in the solution, the more secondary nucleation we would expect.
The units of 89 depend on the values of 8 and , but the units of  are still #/m3∙s.
Typical bounds on  are given on page 60 of Tavare [51] as 10e − 10He #/kg∙s for

primary nucleation, and 10f − 10H #/kg∙s for secondary nucleation. Nucleation order
tends to be 0 < S < 5.

2.4.2

Growth

While some nucleation is required in an unseeded solution to “get the ball rolling”,
nucleation is generally undesirable in crystallization processes. Crystal growth is the
main phenomenon we wish to encourage in our crystallization. More growth means
larger crystals, and larger crystals are generally better. During crystal growth, solute
molecules integrate, layer by layer, into the crystal lattice. Typically, growth is generally
bottlenecked by the surface integration step, where incoming solute molecules must
possess a particular intramolecular configuration to be able to bind properly to the crystal
lattice. Growth may be diffusion limited as well. While other expressions do exist, as
given by [112], the most common form of the growth rate encountered in the literature is:
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P = 87
Where P is the growth rate (µm/s),

7

(2.6)

is the supersaturation ratio, 87 is the growth rate

constant, and T is the growth order. Typical bounds on P are given by Tavare [51] as

0.001 < iPi < i1 µm/s, and typical bounds on the kinetic constants are 0.001 < i 87 < 1
µm/s, and 0 < T < 3. For size dependent growth, a common expression is [113]:
P = 87

7

(1 + )(

(2.7)

A common feature (and manufacturing difficulty) of pharmaceutical drugs is their very
slow growth rates and poor water solubility (~100-101 µg solute/g H2O) [114].
Pharmaceutical API’s are typically complicated organic molecules with many internal
degrees of freedom [22], which creates a high entropic barrier to surface integration, even
when enthalpy change is highly favorable. Growth rate dispersion is the phenomena
observed where crystals of the same size, under the same ambient conditions, display two
different growth rates. The root cause of this phenomena is the intrinsic stochasticity of
crystal growth. The stochastic nature of crystallization is apparent at low liquid volumes,
where it is possible to observe nucleation in one small volume of liquid, but not in
another. Likewise, growth rate dispersion is also a stochastic process (or can be modeled
as such) as solute molecules have a chance associated with themselves at any instant of
time to choose to integrate into the crystal lattice of a given crystals in the slurry.

Chemical additives can stunt growth along certain directions, leading to a preferred
crystal habit [47]. The addition of chemical additives (or, “process control agents”) to the
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crystallizing solution can have a variety of helpful benefits. Typically, one uses additives
with a similar structure to the subject molecule. The presence of even small amounts of
additive can change the relative growth rates between various crystal faces, altering the
crystal’s shape. Additives can also improve the tableting process [21]. The use of
additives is unexplored territory concerning our work. In this thesis, we have only
exploited supersaturation as a control, while a more sophisticated scheme for controlling
crystal shape could use additive concentration as a control as well.

2.4.3

Dissolution

The dissolution rate of pharmaceuticals strongly impacts their bioavailability. When an
oral dosage form is ingested, the excipient binder is digested away in the stomach, and
eventually discharged to the small intestine. In the small intestine, drug uptake is
achieved and the drug finally enters the blood stream. However, the degree of uptake is
dependent on the drug’s concentration at the tissue surface. This of course, depends on
how well the drug dissolves in aqueous solution. Most pharmaceutical drugs are poorly
soluble in water, on the order of a few micrograms per gram. The poor solubility and
dissolution rates have led to many engineering approaches to increase dissolution rate,
including mechanical micronization, and the production of small crystals and
nanocrystals, and amorphous forms. Amorphous solid forms are of interest, since they are
less stable than crystalline forms, and as such exhibit faster dissolution.

55
The gray points in Figure 2.5 on page 44 indicate a solution that is below solubility.
When concentration is below the solubility concentration, the solution is said to be
undersaturated, which leads to the dissolution of crystals. During dissolution, crystallized
solute molecules break of and dissolve back into the solution. This causes the solute
concentration to rise to the solubility curve and attain equilibrium.

Dissolution is

typically much faster than growth, since there is no surface integration step. Some
expressions for dissolution from the literature include [113], [115]:
O=

8% (1 − )%
k

(2.8)

The exponent of the dissolution law is usually 1, which makes for much faster “reverse

growth.” Typically also 8% ≫ 87 . Furthermore, small crystals typically dissolve much

faster due to the Gibbs-Thomson effect [116]. CHAPTER 6 incorporates dissolution into
the framework, in an effort to exploit the phenomena to eliminate fine crystals.

2.4.4

Agglomeration and Breakage

Agglomeration and breakage do not consume supersaturation, but affect the CSD in other
ways. Breakage is typically cause by a moving surface, such as the impeller.
Agglomeration is caused by high surface energy. Both agglomeration and breakage
greatly complicate the solution of population balance equations, since these phenomena
are mathematically expressed as an integral. Further discussion of agglomeration and
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breakage are beyond the scope of this work. A detailed discussion of agglomeration and
breakage are beyond the scope of this work.

2.5

Polymorphic Form and Chiral Form

While this thesis is concerned with the control of crystal size, polymorphism is a critical
quality attribute for pharmaceutical manufacture. We give a brief overview of
polymorphism in this section, as well as recent developments in observation and control
of solid forms. Polymorphism has substantial impact on drug discovery, manufacture, and
efficacy [22], [96], [43], [117]. Some polymorphic forms of an API are more preferable
for pharmaceutical use, due to faster dissolution rates and higher bioavailability. The
proclivity of a substance to take on different polymorphic forms during crystallization
complicates the development, patenting, and manufacture of pharmaceuticals. Desiraju et
al. [96] discusses several industry case studies that led to lawsuits, recalls, and product
failure – namely the anti-ulcer drug Ranitidine (Zantac), and the AIDS drug Ritonavir.
Generally, the thermodynamically most-stable form is preferred to remove the possibility
of a phase change on-the-shelf, but a more bio-active, kinetically-trapped form may be
preferable.
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2.5.1

General Background and Properties of Polymorphs

Solid-phase forms fall into four types: polymorphs, solvates, desolvated solvates, and
amorphous compounds [21]. While these each have their own nuances that are important
to product and process development, for brevity we focus only on true polymorphs. Two
or more different polymorphic forms of a substance possess the same chemical formula,
but have different molecular packing arrangements that generate the lattice [22], [96].
Complicated organic molecules, such as pharmaceuticals, are typically bedeviled by
several polymorphic forms due to many internal and external degrees of freedom for
arrangement [99]. While aspirin only has one known form, carbamazepine has four, and
olanzapine has six [99]. Polymorphism affects a variety of macroscopic properties, such
as color, density, crystal habit, melting point [22], [96], [43], [99]. Internal transport
properties, such as thermal and electrical conductivity, can also substantially differ.
Furthermore, the surface exposure of certain chemical moieties and crystal faces can
impart increased chemical reactivity, dissolution rate, and solubility in one form
compared to another [22], [99], [118]. This is especially true of amorphous solid forms.
Dissolution rate and solubility directly impact the potency of oral tablets, the most
popular dosage form [22]. Many common pharmaceutical unit operations (e.g.
crystallization, freeze-drying, milling) can alter the solid form in difficult-to-predict ways
[21]. Milling and other size-reduction operations are known to induce polymorphic
changes in fed crystals [21]. Maintaining target solid-form and while maintaining other
process variables is also difficult. Reutzel-Edens mentions a study in which the filtration
and drying produced the desired solid-form of the API, but that solvent removal
dramatically altered the crystal size distribution [22].

58
2.5.2

Polymorph observation and control

While critical to product safety and quality, monitoring and control of polymorphic
crystallizations is still poorly understood. Both observation and control of polymorphic
form are major challenges in crystallization [119]. More work is listed therein pertaining
to other process variables, such as concentration and crystal shape. Raman spectroscopy,
near-IR, and mid-IR have been used for observation of solid form previously. Indirect
approaches to polymorph observation and control have been applied [22]. One study
mentioned in [22] successfully prepared one form of an enantiotropic compound by
seeding the process with the desired polymorph, and keeping the temperature below the
intersection temperature on the two solubility curves. Another study inferred
polymorphic form by the investigators noticing that, for their particular API, the
formation of an undesired solvate also formed a quasi-emulsion. Studies using particle
vision measurements (PVM) allowed the research team to identify correct operating
conditions to avoid the emulsion formation, as well as generating the desired non-solvate
form. Solid-form can be ascertained by X-ray powder diffraction (XRD), differential
scanning calorimetry (DSC), relative humidity measurement (%RH), and Laue
diffraction [21]. Such methods however, are not readily amenable to continuous
monitoring. Continuous, quantitative control and monitoring of solid-phase form is a
major research challenge. Some methods for altering the solid-phase form is
manipulation of the solvent used for crystallization. The solvent used can strongly impact
the crystallized polymorph [118]. Supersaturation is theoretically useful as a control,
however, this is only for the production of amorphous forms, and can only be done at
very high supersaturation [21]. Rungisimanon et al. have demonstrated an interesting
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new method for direct and selective crystallization of certain polymorphs using laser
radiation [101], [102].

2.5.3

Chiral Form

The enantiomeric form of the molecules composing a given crystal, while practically
irrelevant to the manufacturing process, can be critical to the final product quality and
safety [120].

About 50% of sold drugs are chiral [21]. Chiral crystallization is often difficult and
expensive to do, rendering many drugs infeasible to produce. A variety of methods are
possible for controlling enantiomeric form, depending upon what level of separation
resolution is required. Direct crystallization into two chiral forms (also referred to as
“preferential crystallization”) can be done by cycling between optically-pure seed crystals
of each stereoisomer, while avoiding nucleation. Often this method is not possible, since
crystallization into a solid racemate is often thermodynamically favorable [21]. Other
methods are also possible for more difficult cases, such as performing the crystallization
in a chiral compound, or reacting the racemate of the API to create a new substance for
which preferential crystallization is possible [21]. Selectivity in chiral form can be
achieved by seeding with the desired chiral form [121], as well as polymorphic form
[118].
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2.6

The Quantitative Framework of Crystal Size Distributions

During crystallization within solution, imperfect mixing causes spatial gradients in
supersaturation. These localized gradients, along with the stochastic nature of growth and
nucleation processes, produces crystals of non-uniform size and shape. To
mathematically describe these variations in crystal size, one uses the concept of a crystal
size distribution (CSD). The framework is discussed in exhaustive detail in the books by
Jones, Garside and Davey, and Randolph and Larson [40], [97], [111]. We present here
the most crucial aspects for understanding this work.

A characteristic length is a chord piercing through a crystal along an arbitrary direction in
  . A chord is any line joining two faces of the crystal polytope. For an irregularly
shaped, nonspherical crystal, (Figure 2.7a) there is no unique chord with which we can
measure the length of a given crystal. A perfectly spherical crystal (Figure 2.7b) is the
only crystal which can be uniquely defined with the single characteristic chord length.
Crystal shape can be described in this way by using multiple length measurements for
each crystal, yielding a multidimensional CSD [111]. Additional lengths provide more
information about the crystal size population, at the cost of increasing complexity. The
distribution of characteristic lengths in a collection of crystals defines the crystal size
distribution, a critical quantity in assessing the performance of crystallization processes
and drug manufacture.
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(b)

Figure 2.7 (a) An irregularly shaped crystal has an infinite number of possible
characteristic lengths one can arbitrarily choose for measuring its size. (b) The only shape
possessing a unique direction is a perfectly spherical crystal, for which all of the possible
characteristic lengths (passing through the sphere’s center) are exactly the same.

Number Density, n (#/m4)

2.6.1

Crystal Size Distributions and General Mathematical Properties.

Ntotal

Mean
size, µ1,0

∞

∫0 ndL= N total

Standard deviation, s

Crystal Size, L (µm)

Figure 2.8 Crystal size distribution and the attendant cumulative summation.

62

The CSD is synonymous with the number density, :() , (#/µm4), where  is the

characteristic length. This quantity gives the number of crystals between size  and

i + i/ , per unit control volume. CSD is a critical variable in measuring the
performance of a crystallization process and the final drug product. Figure 2.8 above
illustrates a typical CSD, its cumulative summation/integral, and several other quantities.
Several possible representations of a crystal size distribution are possible. All crystal size
distributions possess a mean (GH, in the diagram) and a standard deviation (<). On
physical grounds, the number density must be greater than zero everywhere, since we
cannot have negative quantities of crystals. Furthermore, we cannot have negative crystal
sizes, and so we only consider distributions defined for  > 0. Since we would very

much like to share this universe with the crystals, we note that limB→r :() = 0.

Integration over the entire domain will always give the total number of crystals, per unit
control volume, in the control volume. A very similar quantity is termed the number
fraction distribution, 1 (m-1crystals):
1() =

:()

r
s :()/

(2.9)

Where 1 is the fraction of the total crystal population with a size between  and  + /.
r

It is easy to show that s 1/ = 1 . We note that the integrals of any fractional

distribution must have dimensionless units, as 1 is analogous to a probability density
function.
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2.6.2

Volume Size Distributions

Many analytical instruments do not measure number density, but instead measure volume
density, :; (m3crystals/m3external∙mcrystals), given by:
:; () = 86  :()

(2.10)

Where 86 is a dimensionless shape factor (tv6 for spheres), and :; is the volume of the

crystals of size  to  + /. The total volume of all the crystals, per unit of control
r

volume, is given by  = s :; /. Analogous to the number fraction distribution is
the volume fraction distribution, 1; :

1; () =

r

:()

s :() /

(2.11)

r

Just like the number fraction distribution, s 1; / = 1. A variety of other distributions
can be defined, such as mass and area fraction. Area fraction is especially important when
studying chemical reactions on the surfaces of particles, as the exposed area is where the
chemical reaction occurs (either for a direct reaction with the particle surface or a
heterogeneous catalytic reaction).

2.6.3

The Impact of Crystal Size Distribution and Crystal Properties

The CSD is known to impact the efficiency of further downstream processing steps (e.g.
filtering and washing), as well the mechanical strength of pressed tablets for oral dosage

64
forms [24], [37]. It also strongly affects the dissolution kinetics within the human body,
which impact final product quality and safety [21], [37], [122]. There are a variety of
benefits from producing a proper CSD in the produced crystals, such as high
bioavailability and improved tablet stability [21], [37], [49]. Furthermore, good control of
CSD can abrogate the need for various size-reduction processes, such as milling, that are
commonly used in drug manufacture [24], [37], [49]. Generally in crystallization, one
desires the largest crystals possible. Large crystals make downstream processing
operations, such as washing and filtering [97], much easier. For some applications,
extremely small crystals are preferred. The use of nano-sized crystals in drug products is
a possible work-around to the poor solubility of many of today’s drug APIs [123], as well
as for the production of inhalable powders and injectable suspensions [21]. In both cases
however, a narrow CSD is often preferred. More generally than the CSD, a variety of
other crystal properties affect drug performance as well. Table 3 on page 43 summarizes
these properties, the motivation for wanting to control them, and how much
controllability exists in the current state-of-the-art [21], [24], [38], [40], [86], [89], [96],
[97], [43], [124], [125].

2.7

Population Balances

Most chemical engineers are familiar with the four main balance equations in chemical
engineering: mass, energy, momentum, and entropy balance. We shall not state these
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individually, and instead direct the reader to any of the textbooks ([126]–[128]) for an
exhaustive treatment. However, we will state the general form of each equation in words:
/
quantityiofiΨ
w
/ iinitheicontrolivolume
=w

rateiofiΨientering
rateiofiΨileaving
−w
theicontrolivolume
theicontrolivolume

rateiofiΨigenerated
+w
insideitheicontrolivolume
−w

(2.12)

rateiofiΨiconsumed
insideitheicontrolivolume

Where Ψ is any of the four quantities previously discussed. However, the two main
equations of mass and energy balance are not sufficient to model particulate processes.
The main reason for this is due to an infinite number of populations that can close the
same mass balance. Figure 2.9 illustrates the problem geometrically. In the diagram, a
given mass of raw material is operated upon by a process, producing a product. In (a),
both the raw material and product are monolithic. However, in (b) the raw material and
product are discrete particles of different sizes, which have the same total mass as the
original blocks in (a). If individual sizes are important variables, mass and energy
balances alone are not capable of modeling this phenomena; any number of chopped-up
versions of the original blocks in (a) would close those two equations.
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Raw Material

Process

Product

(a)

Process

(b)
Figure 2.9 Depiction of equal mass closures for two different populations of particles.

This is not a problem that can be approximated away or swept under the rug. Particle
phases are widely encountered in engineering processes, and the properties of the
collective population of particles is often critical to ease of processing, and final product
quality [47]. Ignoring the momentum and entropy balances, a third balance equation is
required in addition to the mass and energy balance. This third balance is important to
pharmaceutical manufacture, since particulate phases are so common in pharmaceutical
production. The operations of crystallization, granulation, tableting, etc., produce crystals,
granules, and tablets – all involve discrete particles. The population balance gives a third
conservation law for describing the internal property distribution of populations of
entities. A population balance model (PBM) neatly summarizes all of the operations
occurring in a system that affects the number of particles with a particular set of
characteristics residing within the control volume, such as birth, death, agglomeration,
compression, expansion, and a host of different breakage processes [129], [130]. This
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framework has been used to model all sorts of interesting phenomena involving discrete
particles, such as biological cells, sterilization processes [47], [131], aerosols, solid rocket
engines [111], and polymerizations [47], [131], [132], pharmaceutical granules, purity of
pharmaceutical crystals, and enantiomeric excess of pharmaceutical crystals. The
equation is given by:
i

:
+ E#> ∙ (:) + E0 ∙ (Z:) +  + O = 0


(2.13)

Where : is the number density (#/m4), t is the time,  is a vector of external velocities, Z
is a vector of internal velocities (crystal growth rates),  is the birth function (e.g.
nucleation, breakage), and O is the death function (e.g. breakage, agglomeration). Both 

and O have units of #/m4∙s. The two gradients are taken with respect to either the external

coordinates (@, V, and W), or the internal coordinates (H , H , …, ' for and crystals with

m characteristic lengths). The general population balance equation is a partial differential
equation [111], and solution is generally difficult. Solving this equation coupled with the
other balance equations yields the correct CSD. The equation was first proposed in
Hulburt and Katz [133]. Good introductions to the formulation and solution of these
models are found in the books by Randolph and Larson [111], Jones [40], Garside and
Davey [97], and Ramkrishna [132], as well as the paper by Rawlings [47]. While the
mass balance equation is typically an ordinary differential equation (ODE), PBMs are
partial differential equations (PDE), which are significantly more burdensome to solve.
Solution of crystallization systems is generally difficult for several reasons –the large
number of variables, vast differences in time and length scales, and the inherent
discontinuity of the system due to the phenomena of nucleation, breakage, and
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agglomeration [37], [134]. To solve these equations, we discuss two important methods
used in this work.

2.7.1

The Method of Moments (MOM) and Finite Volume Method

Due to the mathematical structure of PBMs, it is possible to reduce them to a system of
ODEs by an integral transformation known as the “method of moments.” This is a widely
used method for solving PBM equations, and is popular due to the rapidity of solution.
The 8 J moment of the crystal size distribution is given by:
i

r

GI =  :I /

(2.14)



The moment form of the population balance equation is formulated by taking the 8 J

moment of the equation, which expresses the original PBE solely in terms of GI [111].
Instead of a partial differential equation, 8 + 1 ordinary differential equations need to be
solved (the extra equation is the mass balance). This problem is significantly easier to
solve than the original. We discuss this method in greater detail in section 4.4.2.

While easier to solve, the MOM loses the CSD in its entirety, making prediction of the
full CSD impossible. Such information is needed for applications such as matching a
target CSD. Furthermore, depending on the phenomena being modeled, the method of
moments may lead to the “closure problem”, where the 8 J moment equation is

expressed in terms of moments greater than 8, for any 8 [133], [134]. This motivates the
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use of a variety of other integration methods for solving moment equations, such as the
quadrature method of moments. Accurate solution is done by decomposition to a large
system of ODEs, using the method of weighted residuals or the finite volume method.
The finite volume method has been applied to the modeling of a multi-segment plug flow
crystallizer previously by Alvarez and Myerson [135]. Number density may itself be a
function of external position, motivating the use of combined CFD-PBM models. The
approach has been used to model impinging jet and antisolvent crystallizers [136]–[138].

2.7.2

More Sophisticated Population Balance Modeling Approaches

There has been much work done with computational fluid dynamics (CFD) simulations
using special software packages, to clearly examine what the flow patterns are within the
crystallizers. These models involve not only the population balance equation, but the
fluid transport equations as well. The k-ε model has been used to investigate turbulent
effects [40]. While these simulations do provide useful data in the form of shear profiles,
temperature profiles, and the location of solids in the crystallizer [44], they are timeconsuming to run, and the countermeasures one can take on scale up are still limited.
Furthermore, if prediction of changes to the CSD is desired, a combined CFD-PBM
simulation is required, to account for spatial variation in particle number density. Such
simulations are even more time-complicated than the original CFD simulations [45].
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Essentially all phenomena in crystallization are random in some way. Nucleation,
breakage, growth, and agglomeration are all based on some chance encounter between
either two particles, or a particle and a molecule for growth, or an ensemble of molecules
for nucleation [139]–[141]. Monte-Carlo methods are based on using computer-generated
random numbers to simulate physical random (or presumptively random) phenomena.
Braatz has discussed several papers which utilized stochastic PBM models and were
solved with MC methods [37]. MC methods are able to model this type of phenomena in
fine detail, but are computationally burdensome. We note that MC is a general tool, and
has been applied to crystallization in other ways to crystallization other than solving the
PBM equation. Jones has described the use of MC to explicitly account for a residencetime distribution in an MSMPR crystallizer [40].

2.7.3

Current Challenges in Continuous Crystallization and Population Balance
Modeling

Challenges abound in the application of process systems engineering knowledge to
pharmaceuticals. This thesis fills an important literature gap by addressing the need for an
integrated modeling, optimization, and design framework for the identification of optimal
crystallizer designs. This framework can be applied to many other crystallization systems
which have not been rigorously modeled, such as some of the crystallizers described in
CHAPTER 3.
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Currently, general solution of the population balance equation is not known, and
numerical methods tend to exhibit significant tradeoffs in speed and accuracy [134].
Speed is required for utilizing the model for model-predictive control, and accuracy is
required to make the benefits of optimal control worthwhile.

Related to the issue of robustness is the issue of dynamic stability. Due to the high
nonlinearity present in crystallization systems, the effect of time usually requires
numerical solution to observe on the CSD. In MSMPRs, oscillations in the CSD are a
known and undesirable phenomena. Dynamics in general have been studied for the
conventional batch and MSMPR crystallizers, as well as networks of MSMPRs. However,
newer crystallizer designs, such as the MSMA-PFC, have not had such analyses done for
them. Furthermore, in newer crystallizer designs (such as the MSMA-PFC), it is
unknown what type of dynamic behavior may be present, e.g. limit cycling or chaos.
Bifurcation analysis of such systems is nearly impossible to do analytically. Rigorous
computational studies are one method addressing this literature gap.

Another challenge, separate from the mathematical difficulties, is the issue of parameter
estimation. The full description of the process requires a great deal of information [40],
including solubility data, crystal density, liquid transport properties, crystal growth rate(s),
and nucleation rate [40]. Accurate estimation of kinetic parameters for growth, nucleation,
and dissolution is one of the most difficult hurdles to surmount in constructing an
accurate crystallization PBM [37], [47]. As pointed out by Rawlings [47], the results
produced by model-based optimizations rely upon estimated parameters, and as such, will
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be sensitive to experimental error. Without very accurate parameter estimates, all of the
effort expended upon optimizing the crystallization equipment and process operation may
be for naught, with virtually no benefit realized. This goes not only for continuous
crystallization, but the entire CPM flowsheet. Model complexity becomes even more
acute when phenomena such as size-dependent growth, non-uniform residence-time
distributions, agglomeration and breakage, and growth-rate dispersion are added to the
model [47]. The complicated nature of such models has motivated the use of MonteCarlo methods for their solution [40].

2.8

Multiobjective Optimization in Crystallization Design and Research

We have utilized multiobjective optimization extensively in our work in CHAPTER 4. In
preparation for this chapter, we provide the reader with useful background information on
multiobjective optimization. Multiobjective optimization is a generalization of scalar
optimization which accounts for the common situation when the decision maker has
multiple conflicting objectives he wishes to optimize over. In general, global
optimization of each function at the same time is unattainable [142]–[144], thus
motivating the concepts of Pareto optimality, trade-off, and non-dominated solutions.
This framework has been applied to batch crystallization by several workers [120], [145].
Such a framework appears quite applicable to analysis of PFCs, since it provides detailed
information on what CSDs are attainable. Bhat and Huang [120] applied the approach to
enantioselective crystallization by incorporating enantiomeric excess into one the
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objectives for maximization, in addition to maximizing size, while minimizing  and
batch time. Sarkar et al. [146] simultaneously extremized several quantities, and supplied
Pareto frontiers.

Typically in crystallization control, one desires larger crystals with compact shape, since
these have superior filtering and dry properties. However, sometimes smaller crystals,
which dissolve faster, are preferable. The purpose of this section is to give the reader a
brief background on the subject of multiobjective optimization (MOO) and discuss
several important issues related to the practical solution of MOO problems. This section
draws heavily from the books by Deb [147], Gen and Cheng [148], and Chambers [148],
which give in-depth discussions of evolutionary algorithms applied to multi-objective
problems in engineering.

2.8.1

Basic Problem Formulation

The standard formulation for an MOO problem is:
:
1 (3) 1f (3) ⋯
3 H
i

1' (3)

Subject to:
\(3) ≤ 
](3) = 
3BC ≤ 3 ≤ 3DC

(2.15)
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Multiobjective optimization is a natural consequence of the fact that real problems,
especially in engineering, often cannot be characterized in terms of a single objective.
Frequently, we must optimize over a variety of objectives, such as capital cost, operating
cost, volume, weight, energy consumption, and other objectives specific to a particular
problem. No single design can simultaneously optimize all objectives in the vector.
2.8.2

Pareto Optimality and the Pareto Frontier

The Pareto-optimal (or also, “non-dominated”) set of solutions to an MOO problem is the
MOO analog of the global minimum for a single-objective problem. Due to multiple
objectives though, the solution is expressed as a set of points instead of a single point.
These points describe a curve, called the Pareto frontier, for which a tradeoff exists
between any two points on the curve. When a point lies on the Pareto frontier, moving in
any direction leads to a desirable reduction in one objective and a concomitant,
undesirable increase in another objective. In mathematical terms, the globally-optimal
Pareto frontier satisfies the property that:
1∗ (3) ≤ 1 (3)

i

(2.16)

for all feasible 3 and for all 1, 2, . . . ,  objectives. That is, there is no point that can
improve any at least one of the objectives while leaving the others unchanged.

2.8.3

Use of the Genetic Algorithm

Many methods exist for solution of problem (2.15), which depend on the difficulty of the
problem. We do not discuss gradient-based approaches in this work, as these approaches

75
are of little use in crystallization problems. The most direct method for solving an MOO
problem is by stochastic optimization. Many such schemes exist, such as simulated
annealing, bacterial foraging, ant-colony, and particle-swarm optimization. In this work,
we have used the genetic algorithm (GA), which mimics the Darwinian process of natural
selection to generate the Pareto frontier. In the GA, a pool of solutions are first generated,
and the objective function is evaluated for each of them. The “fittest” solutions are
allowed to pass on to the next generation. Then a variety of mutation, transposition, and
selection operators create a new set of “child” solutions created from the “genes” of the
parent solutions. This helps preserve the good qualities of the prior solutions, but offers a
chance to improve the solution further by moving elsewhere in the search space. Unlike
gradient-based approaches, the GA is robust against local minima.
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CHAPTER 3. CURRENT LITERATURE ON CONTINUOUS
CRYSTALLIZATION TECHNOLOGIES

We present in this chapter a more specific literature review focusing solely on continuous
crystallization designs that have been proposed and tested in the literature. The purpose
of this chapter is to expose the reader to the breadth of the continuous crystallization
literature. It also helps place our work in the greater context, as we have investigated in
this work solely the MSMA-PFC. A handy table at the end of this chapter summarizes the
key findings and experimental attributes of many studies in the field of continuous
crystallization.

3.1

The MSMPR, MSMPR Cascade, and CoFlore™ Crystallizers

The mixed-suspension, mixed-product removal (MSMPR) crystallizer is the workhorse
of large-scale chemical manufacture, used for productions of ~1-50 tons/day [47]. It is
the crystallization analog of a continuous stirred-tank reactor (CSTR). Large, scaled-up
examples of such devices can be seen in Larsen et al. [38]. Aside from large-scale use,
the MSMPR (as well as batch crystallizers) is used often in the laboratory for
experimentally determining growth and nucleation rates, and also for detecting sizedependent growth [47], [51].
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Mascia et al. utilized MSMPRs for their crystallizations in their study of a continuous
tablet manufacturing pilot plant [23].Quon et al. [149], Zhang et al. [150], and Alvarez et
al. [151] demonstrate the use of multiple MSMPR’s in series for cooling and antisolvent
crystallization of pharmaceuticals. Newer MSMPR technologies have explored novel
new mixing methods to allow for better process control. A highly intensified version of
the MSMPR cascade is the CoFlore™ reactor, which has been recently applied to the
continuous reactive crystallization of N-iodomorphlonium salt by Browne et al. [152].
Originally developed for chemical reactions, the CoFlore™ reactor utilizes several
agitated compartments, along with bulk agitation with a linear oscillator, to keep solids
suspended while crystallization is taking place [152]. A major problem with continuous
crystallizers of all kinds is the issue of plugging and fouling, and high shear mixing is one
method of forestalling buildup. Unlike larger MSMPRs, the smaller Coflore™
crystallizer offers superior mixing characteristics, enabling swift mass transfer and
avoiding the problems with solid suspension discussed in section 2.1.4. Narducci et al.
[153] used power ultrasound as well the conventional stirrer.

3.2

Plug-Flow Crystallizers

The plug-flow crystallizer (PFC) is analogous to the plug-flow reactor (PFR). It can be
shown analytically that the MSMPR cascade, in the limit of infinitely small CSTRs,
asymptotically converges to the PFC [154]. Cascades generally converge to a PFC within
about 5 units. For fast crystallizations, PFCs can be practical, while slow crystallizations
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require too great of a residence time (and thus too slow of flow velocity) to be useful. A
common feature of plug-flow crystallizers (and other types discussed in §3.3) in the
recent literature on pharmaceutical crystallization is the exploration of various mixing
methods. Among others, we observe vortex mixers (“Roughton” type [155]), impinging
jets [136], [137], [156], and static mixers (e.g. the Kenics mixer [135]). Such mixers have
been investigated for flow-dependent reaction syntheses previously, and more recently
for use in crystallization research. The topic of static mixers is discussed at length in the
review by Thakur et al. [157]. Generally, such mixers are found to be significantly more
efficient than active mixers, and, with proper design, can rapidly achieve plug flow.
Typically, good mixing can be achieved using vortex mixers, or static helical mixers.
Simulations by Woo et al. [136] show that vortex mixers possess mixing times well
below the induction time of crystallization, which ensures that there are no confounding
effects from supersaturation gradients. Eder et al. [158], [159] have investigated a stagewise cooling PFC for continuous aspirin crystallization. Their PFC consists of a flexible
coiled tube, which permits a long residence time, but occupies little space. Control over
the supersaturation trajectory is achieved by chilling separate coiled sections. This
permits the creation of a clearly-defined temperature profile along the length of the PFC.
For the case of antisolvent crystallization, The plug flow crystallizer is often not a
practical tool for pharmaceutical crystallization, since residence times must be so long to
achieve a larger crystal size. This leads to very low flow rates and low velocities, which
leads to settling of the crystals and fouling of the inner surfaces with API. Very low flow
velocities also lead to self-contradiction if the “plug-flow” crystallizer is operated in the
laminar flow regime. Lawton et al. [160], used a PFC augmented with baffles and a
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pulsating “thumper” to drive flow continually back and forth, while maintaining a net
positive forward flow. The logic in using these baffles is to obtain better turbulent mixing
along the length of the crystallizer, while avoiding high flow rates which would normally
be necessary to produce it. High velocity is achieved without shortening residence time.
FBRM was used for observation of crystal size via chord-length distribution. Their
results showed vast reduction in production time.

3.2.1

Multi-Segmented Plug-Flow Crystallizers

A feature of this thesis is investigation into using multiple crystallizer segments in series.
This allows for spatial control over supersaturation in on dimension, which is not possible
in a stirred tank (batch or continuous) crystallizer. Variation of supersaturation with
length allows for improved control over growth and nucleation, which leads to a better
final crystal product. Prior work in this area has been done by Alvarez on antisolvent
crystallization, Majumder and Nagy on the modeling of cooling crystallization, and
Ridder et al. on modeling antisolvent crystallization. Alvarez and Myerson have
investigated a multi-segment PFC, with separate antisolvent injections into each stage
[135]. Their segmented PFC system was modeled with a set of PBM equations and a
mass balance equation, and compared to experimental results. The kinetic and solubility
parameters of ketoconazole, flufenamic acid, and L-glutamic acid were determined
experimentally for use in the model. FBRM was used for measuring CSD, and comparing
to model prediction, though no feedback control was used. In that work, a Kenics screw-
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type static mixer was used to ensure good homogenization of the liquor and antisolvent
streams, but other approaches have been used as well. Majumder and Nagy investigated
the use of in-situ dissolution in plug-flow cooling crystallization in order to eliminate fine
crystals [113]. Ridder et al. investigated the crystallization of flufenamic acid via a
simulation and optimization-based study [161], [162]. The sensitivity to kinetic
crystallization parameters was investigated as well.

3.3

Other Types of Continuous Crystallizers

Nguyen et al. [163] have investigated the use of this crystallizer. In a CT crystallizer,
liquor flows into the hollow gap between a cylindrical shell and a concentrically-located
spinning cylinder. When rotated at high speed, the fluid eventually exhibits CouetteTaylor flow, where the fluid segregates into an “accordion” of concentric toruses, with
fluid rotating concentrically about the axes of the individual toruses rather than about the
axis of the spinning cylinder. Unlike the COBC, which directly compartmentalizes
various elements of fluid, each torus might be considered its own “compartment”, and
mixing occurs within toruses as well as between them. These toruses can be modeled as
separate compartments in a compartment flow model. The CT crystallizer allows for high
slurry velocity, which improves mixing and avoids the problems of settling and fouling at
low velocity. However, residence time can be controlled purely by inlet flow. Thus a
decoupling can be achieved between flow velocity and residence time for the continuous
CT crystallizer.
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A type of spray-drying crystallization using electrically-stimulated liquid jets has been
investigated by Wang et al. [123] for the production of carbamazepine nanocrystals.
Similar to spray-drying, an electrospray device generates fine jets of liquid by applying
electric potential to a saturated liquid solution. The charged fine droplets naturally repel
each other in flight, until they land on a grounded surface. Rapid evaporation leads to
amorphous crystals. This approach is interesting, in that it provides a continuous
production route to a particular (though, in this case, unstable) solid-form, in the nanosized regime. Significantly more work could be done in terms of modeling of this system,
such as population balance modeling of the generated droplet cloud.

Another design is the electrospray crystallizer. This type of device, originally developed
for plastic injection molding, utilizes two opposing streams of high-velocity liquid
sprayed at an intersecting point. The region where these two streams collide creates a
zone of intense mixing, avoiding the aforementioned trouble with supersaturation
gradients. Details about the design of this crystallizer can be found in the original patent
[156]. The Braatz group at MIT has done extensive work on the modeling, simulation,
and optimization of this type of crystallizer [136], [137] for the case of the drug lovastatin
and L-histidine. Woo [136] performed combined CFD-PBM-micromixing simulations of
the impinging jet crystallizer within the mixing chamber. Their results show that, given a
sufficiently high Reynolds number, thorough mixing is achieved before fluid exits the
mixing chamber. The results of that study were further used in [137], where the obtained
crystal size distributions from the previous modeling were used as decision variables in
an optimization problem. By utilizing a repertoire of known CSDs for given jet velocities,
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a series of quadratic programming and nonlinear least squares optimizations were solved
to identify the optimal control strategy for seed input into a CSTR. By adjusting jet
velocity as a function of time, a variety of peculiar CSDs were obtained. Their numerical
results show that, theoretically, significant control over the target CSD exists.

3.3.1

Continuous Microcrystallizers

Borrowing from the field of chemical reaction engineering, is the concept of the
microcrystallizer [164]–[166]. Due to the aforementioned problems with crystallizer
scale-up, an alternative approach is to use multiple, smaller continuous flow devices in
parallel. Once a single microreactor has been design and tested thoroughly, the process of
scale-up to a larger mass flow rate is greatly simplified, as multiple units can be used in
parallel instead of enlarged. This is termed “number up”, as opposed to “scale-up.”
However, the technical problems of fluid distribution and lack of flexibility in inputs
leaves “number up” can still be challenging for proper scale-up [167]. Microcrystallizers
have pharmaceutical use as high-throughput screening platforms for drug discovery and
development, and lab-scale process optimization [167]. Currently, they are not usable for
drug production, due to plugging and fouling of the vessel interior [167]. Microfluidic
crystallization is mainly used for high-throughput screening of optimal experimental
procedures for protein crystallization. However, use has been demonstrated for highthroughput screening of pharmaceutical salt forms and polymorphs. Llinas and Goodman
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cite a case where over 2000 screening experiments were performed for polymorph
identification using only 2 grams of API [99].
3.4

Table of Continuous Crystallization Technologies

Table 3 below summarizes a wide variety of studies encompassing these crystallizer
designs.

PFC

Multisegment
PFC

PFC

Eder et
al. 2011
[168]

Alvarez
and
Myerson
2010
[135]

Ferguson
et al.
2012
[155]
Antisolvent

Antisolvent

Cooling

Ethanol/water

• Methanol/water
• Ethanol/water
• Water/acetone

Ethanol

Benzoic acid

•
Ketoconazole
• Flufenamic
acid
• L-Glutamic
acid

Aspirin

Table 4 Table of continuous crystallization literature related to pharmaceuticals.
Crystallizer
Solute
Paper
Mode
Solvent/Antisolvent
Type
Key Findings

• Moderate
supersaturation
encourages growth;
• Effect of input
avoids nucleation.
seed mass on
• More seeding
average crystal size.
reduced final size.
• Fast convergence
to steady-state.
• Improvement in
• Effect of
average crystal
antisolvent
properties for some
sidestream injection
sidestream
configuration on
configurations.
CSD.
• Model doesn't fit
• Compared
well, unless
population balance
growth-rate
model prediction to
dispersion is
experimental result.
accounted for.
• Investigated
• Can achieve much
ability to monitor
lower crystal sizes
process using in-situ
than batch.
PAT (FBRM, ATR
• PVM can't see
FT-IR, PVM)
smaller crystals.

Investigated
What?
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Two
MSMPR
cascade

Three
MSMPR
cascade

MSMPR

Quon et
al. 2012
[149]

Alvarez
et al.
2011
[151]

Narducci
et al.
2011
[153]
Cooling

Cooling

Reactive

Water

Acetone

N/A

Adipic acid

Cyclosporine

N/A

Table 4 continued.

• Effect of ultrasound
probe power on
crystal properties and
process dynamics.

• Estimated kinetic
parameters for
cyclosporine
crystallization,
• Effect of recycle
ratio on yield and
purity

• Crystal size greatly
reduced by
sonication.
• Fouling interferes
with heat transfer
and sonication.
• Agglomeration
reduced by
sonication.

• Significant
tradeoffs between
purity, yield, and and
mean size.
•

• Crystallized aliskiren
• Significant tradeoff
hemifumarate, and
between crystal
determined kinetic
purity and crystal
parameters.
yield.
•
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85

CouetteTaylor (CT)

Lawton
et al.
2009
[160]

Nguyen
et al.
2012
[163]

Wang et
al. 2012 Electrospray
[123]

Continuous
oscillatory
baffled
crystallizer
(COBC)

Parallel
disk

Antisolvent

Cooling

Methanol

Water/Methanol

Unwritten

Carbamazepine

Guanosine 5monophosphate

Proprietary

Table 4 continued.

• • Investigated
electrical current,
concentration, and
flow rate on
obtained crystals.

• Effect of feeding
configuration and
residence time on
crystallinity and
mean crystal size.
• Effect of rotational
speed on
crystallinity, yield,
and mean crystal
size.

• Effect of
oscillation
parameters and
cooling rate on CSD
and habit.

• Rapid
crystallization
produced product.
• Obtained crystals
of sizes ~300-1700
nm

• Requires shorter
residence time
required vs.
MSMPR.
• Increasing
crystallinity and
yield with
increasing
rotational speed;
decreased mean
size.

• Larger sizes with
slower cooling rate.
• 20%-50%
decrease in capital
cost vs. batch.

86

86

Besenhard
et al.

Segmented
plug flow
Cooling

Ethanol

Acetylsalicylic
acid

Table 4 continued.
• Injected air into
line to create
segmented “slug
flow.”
• Cooling
crystallization with
many variables
explored using a
small DOE
approach.

• Breakage is
negligible.
• Agglomeration
observed
• Sensitive to initial
seed mass loading.

87

87
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CHAPTER 4. MULTIOBJECTIVE OPTIMIZATION AND ROBUSTNESS
ANALYSIS OF THE MULTI-SEGMENT, MULTI-ADDITION PLUG-FLOW
ANTISOLVENT CRYSTALLIZER (MSMA-PFC)

4.1

Abstract

In this chapter, we present optimization and simulation results related to a new type of
crystallizer for the production of pharmaceutical APIs. We develop the population
balance and mass balance model framework, as well as the multiobjective optimization
framework for investigating the design of the crystallizer. The governing model equations
are derived and presented. Landscape plots of mass-mean size ( ) and coefficient of
variation () indicate great sensitivity to flowrate and nonconvexity, necessitating the
use of stochastic optimization via the genetic algorithm. Using multi-objective
optimization, we calculated optimal designs for this crystallizer in terms of maximizing
 and minimizing . A tradeoff exists between these two quantities. Mean size was
improved over prior literature results while maintaining similar spread. The optimal
solution was sensitive to uncertainty in the kinetic parameters of nucleation (89 ) and
growth (87 ). Lastly, we have investigated the sensitivity to flowrate for the MSMA-PFC
using a simple Monte-Carlo technique. The greatest sensitivity is observed in the first and
third segments, while the second and fourth have little process impact. This work is
substantially composed of work from the paper [161]. Adapted with permission from B. J.
Ridder, A. Majumder, and Z. K. Nagy, “Population Balance Model-Based Multiobjective
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Optimization of a Multisegment Multiaddition (MSMA) Continuous Plug-Flow
Antisolvent Crystallizer,” Ind. Eng. Chem. Res., vol. 53, no. 11, pp. 4387–4397, Feb.
2014. Copyright 2014 American Chemical Society. It also contains work substantially
composed of from the conference paper [162]. Adapted with permission from B. J.
Ridder, A. Majumder, and Z. K. Nagy, “Population balance model based multi-objective
optimization and robustness analysis of a continuous plug flow antisolvent crystallizer,”
American Control Conference (ACC), 2014, pp. 3530–3535, Jun. 2014. Copyright 2014
IEEE.

4.2

Introduction

As discussed in CHAPTER 1, financial pressures have caused the pharmaceutical
industry to express interest in the development of new manufacturing technologies [3],
[7], [15]. These problems translate into high manufacturing costs, though little attention
has been historically paid to the problem. One such technology branch that is being
researched is advanced crystallization processes. Crystallization is a major separation unit
operation in fine chemical and pharmaceutical manufacture. The overwhelming majority
of drugs are organic molecules crystallized from solution [24], [113], [169].
Predominantly, pharmaceutical crystallization is done batch-wise, despite clear evidence
of the economic advantages of continuous manufacturing – such as steady-state operation,
lower material hold-up, and superior control over the state of the final drug product [5],
[24], [160].
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An optimization problem has been indirectly suggested in the literature by Alvarez and
Myerson [169]. Alvarez had attempted to improve the crystal output properties by
manipulation of injection configuration and/or antisolvent flowrates in an MSMA-PFC.
In previous work on batch crystallization, the goal was to manipulate supersaturation as a
function of time to achieve an optimal set of crystal properties at the conclusion of the
batch [145], [146], [170], [171]. Analogously in this work, we have manipulated the
supersaturation profile in order to optimize the crystal properties at the outlet. The
difference is that the supersaturation profile in the batch case is with respect to time,
while here it is with respect to length into the crystallizer.

We have optimized an MSMA-PFC for the production of flufenamic acid, an antiinflammatory drug [169], [172]. By altering the antisolvent flowrates in the various
sections, the supersaturation can be controlled along the length of the crystallizer. The
supersaturation within a segment strongly affects the nucleation and growth kinetics
therein and thus gives us a method for manipulating the product CSD at the outlet. The
process is modeled using a steady-state population balance model (PBM), and is solved
using the method of moments as well as a high-resolution finite volume scheme [113],
[173], [174]. A similar work has been performed by Vetter et al. [17] In that work, the
authors investigated the attainable product regions of crystal size for a given residence
time in continuous crystallizers. Such studies are helpful in estimating the performance
and flexibility of such systems for practical use, with the impact on the final product in
mind.
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4.3

Methodology

To investigate this continuous flow system, we utilize a multi-objective optimization
(MOO, also known as “vector optimization”) framework. Such a framework is useful for
fully investigating the capabilities of particular design. The solution of MOO problems is
cast in terms of finding the non-dominated set of possible solutions, e.g., the solutions for
which it is impossible to improve one objective without degrading another. This nondominated set is referred to as the “Pareto frontier.” Such a framework is highly
amenable to crystallization problems, which often have a multitude of conflicting
objectives in the problem definition. MOO has been applied previously to batch
crystallization processes [145], [146]. We explore the multi-objective optimization (MOO)
of the MSMA-PFC, with the objectives of maximizing the mass-mean size ( ) and
minimizing the coefficient of variation (). We show in this work that nonconvexities
are encountered in the search landscape, making a stochastic optimization algorithm more
appropriate. A widely-used solver for finding the Pareto front is the non-dominated
sorting genetic algorithm (NSGA-II), which can efficiently identify the non-dominated
set, and handle constraints[175], [176]. We also investigated the sensitivity of the Pareto
front to uncertainty in the kinetic parameters. The simultaneous design and control
framework for the MSMA-PFC is evaluated and it is shown that with appropriated
crystallizer design, that takes the possibility of improved control into account, can
improve product quality significantly.
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4.4

Model Diagram, and Governing Equations

Saturated ethanolic solution
of flufenamic acid

n1
C1

n1end
C1end

nN
CN

n2
C2

nNend
CNend

...
unseeded, n0 = 0
C0 = Csat (saturated), kg API/m3 solution
A1
Vfeed, ml/min

segment
1

segment
N
A2

An

product

water (antisolvent) streams, ml/min

Figure 4.1 Model of segmented plug flow crystallizer system.

The idea behind the MSMA-PFC is to distribute antisolvent along the length of the
crystallizer, which allows for the control of supersaturation in one dimension. The
MSMA-PFC is based on the setup in Alvarez and Myerson [169]. It is modeled as a
series of ideal plug flow elements, and antisolvent is added at the beginning of each
segment (see). Each of the  segments is a separate PFC.  is the antisolvent flow rate

added to the  Ji segment. The inlet at the far left is the feed flow rate (##% ), with an

initial concentration of solute ( ) and a seed crystal size distribution (CSD), : . The

population and mass balance equations are solved for each segment, and the output of
one segment becomes the input to the next segment. The CSD (:) and concentration ()
are adjusted for the dilution induced by the addition of antisolvent. The final CSD, : , is
used for formulating the multi-objective optimization problem. The optimization problem
is solved by manipulating the antisolvent flow rates in each segment ( ). It is assumed

that each of the  segments is a separate PFC, running in steady-state, isothermal
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operation. The solvent and antisolvent streams are assumed to mix together perfectly, and
attain plug flow. In this work, we consider only the unseeded case (: = 0); however the
same framework can be applied for seeded operation. The population and mass balance
equations are solved for each segment, and the output of one segment becomes the input
to the next segment. Isothermal operation abrogates the need for solution of the equation
of energy.

4.4.1

Model Equations

The model equations for the crystallizer design explained above consist of a set of
population balance equations (PBEs) describing the evolution of the CSD along the array
of plug flow crystallizers, coupled with mass balance equations that take into account the
depletion of solute concentration in the solution due to crystal growth and nucleation.
Population balances are a key tool in the model-based control of crystallizers [40], [51],
[70], [97], [124], [177]. In this work, our seed distribution at the inlet is zero; the process
is unseeded. Number density changes along the tube length since birth and growth
processes depend on the supersaturation ( ). The model equations for the steady-state
system are discussed below. The PBE for a PFC is derived by crossing off the irrelevant
terms in the general equation given in (2.13):
i

0










+ > (=> :) + ? =? : + ) (=) :) + B (P:) −  + O = 0

(4.1)
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Since we are using the average velocity, => v@ = 0. If one-dimension flow is assumed,
then the other two velocity components are zero. We assume size independent growth,
e.g. P v = 0. Regarding the birth function, only nucleation occurs, which means only
crystals of size  enter the system. This is modeled using a Dirac delta function as

 =  F( −  ), whereiF( −  ) has units of m-1. There is no death function here, e.g.
no agglomeration and breakage. Post-cancellation, the steady-state PBE for the MSMAPFC is:
(!)
=>

:(!)
:(!)
(!)
(!)
+P
=  F( −  )
@


where the superscript denotes the

J

(4.2)
(!)

segment of the MSMA-PFC, => is the average

velocity of the fluid, :(!) is the number density, and @ is the length along the crystallizer.

The average velocity is computed by adding up the total volumetric flow rates of solvent
and antisolvent in the particular PFC segment, and dividing by the cross-sectional area of
the PFC. In the PBM literature,  is referred to as the “internal coordinate”, while @ is
referred to as the “external coordinate.” Our boundary conditions are [111]:
(!)
:(!) (0, @) =  vP (!)

(4.3)

:(!) , @!,0  = ! :(!H) , @!H, 

(4.4)
(!)

and :(H) (, 0) = 0 (e.g. the process is unseeded). Furthermore,  is the nucleation rate,

P (!) is the crystal growth rate and ! is the dilution factor. At the entrance of each PFC
segment, the CSD and solute concentration were adjusted by multiplying with a factor
which corrects for the dilution:
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! = i

!H

##% +  
!

##% +  

.

(4.5)

This factor is derived by performing a mass balance around all PFC segments and mixing
points up to and including the

J

i PFC segment ( = 0, and = 1ifor the first PFC

segment). Equation (4.2) tracks the CSD as solution passes through the PFC array. In
addition to eq. (4.2) the solute mass must be tracked. We do this by simultaneously
solving the mass balance equation:
(!)
=>

r

/ (!)
= −3K& 86 P (!)  f :(!) i/,
/@

(4.6)



wherei (!) is the concentration of dissolved solute in the liquid phase, K& is the solid

crystal density, and 86 is the crystal shape factor.  decreases along the length of the

array via not only the processes of growth and nucleation, but also by addition of fresh
antisolvent. Thus, the mass balance boundary condition is (@ = 0) = i  and
 (!) @!,0  = !  (!H) @!H, 

(4.7)

Equation (4.6) accounts for the depletion of dissolved solute from the supersaturated
liquid phase by the layer-by-layer areal deposition of solute matter upon the exterior
surfaces of nucleated crystals. Other ancillary equations are, the growth and nucleation
rate equations:
P (!) ( ) = 87 (

) ,

(!) 7

 ( ) = 89 (

) ,

(!) 9

and the percent antisolvent ratio, supersaturation, and solubility curve:

(4.8)
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%(!)

*+

= 100

Where



¡¢ +


¡¢

+ i£i¤¢

,

(!)

(!)

(!)

%(!)

=  (!) −  ,  =  ¥@^(− *+

),

(4.9)

is the supersaturation, 87 , T , 89 , and S are growth and nucleation rate law

parameters, *+% is the antisolvent volume percentage,  is the solubility concentration,

and  and  are fitted parameters for the solubility curve. The solubility and kinetic

parameters used in this work are those regressed by Alvarez and Myerson for flufenamic
acid [169]. Numerical values for the parameters discussed here are given in Table 5
below. Prior to the first injection, no antisolvent is in the feed stream.
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Table 5 Parameters for crystallization optimization from Alvarez and Myerson [169].
Copyright 2014 IEEE.
Parameter
Value
Inner diameter, m
Initial concentration,  , mg/m3

Solubility parameter,  , mg/m3

Solubility parameter,  , dimensionless
Shape factor, 86 , dimensionless

1.27i × i 10
1.24i × i 10¨
3.36i × i 10©
0.108

t/6i(≈ i0.524)

Crystal density,iK& , mg/m3

1.47i × i 10«

Segment length, m

0.6

Mother liquor flowrate, , ml/min
Growth rate constant 87 , m/s

Growth law exponent, T, dimensionless

100

9.9i × i 10¨
1.1

Nucleation rate constant 89 , #/(m3·s)

1.5i × i 10©

Antisolvent concentration in initial solution (mg/m3)

0

Nucleation law exponent, S, dimensionless

4.4.2

2.1

Solution of Model Equations

Depending on the application or desired information, some solution methods are more
appropriate than others. Typically various method of moments (MOM) are used to solve
the population balance equations (PBEs), when only moments of the CSD are required,
e.g., standard method of moments (MOM) [133] and quadrature method of moments
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(QMOM) [134], [178]–[180]. The importance of moments lies in the convenient
simplifications they impart to the solution of crystallizer modeling equations [40], [111],
[181]. In the method of moments, progressively higher moments of (2.13) are taken,
reducing the complicated, coupled, ODE-PDE system to a system of  + 1 ODE’s; the

 moment equations, plus the mass balance in (4.6). The 8 J moment of the CSD is
given by:
(!)

r

GI =  I :(!) (, @)/


(4.10)

The physical meaning of the moments is straightforward: G is the total number of
crystals, GH their total length, Gf their total surface area, and G their total volume – all

per unit of control volume [111], [181].To obtain the moment form of the PBE, first take
the 8 J moment of the entire equation:


r
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(4.11)

We can take the derivative out of the integral on the leftmost term on the lefthand side:
(!)

=>
r

(!)

r
/GI
:(!) I
(!)
+ P (!) 
 / =  I
/@



(4.12)

The term s :(!) v I / can be integrated using integration by parts to finally obtain
the 8 J -moment equation:

(!)

(!)

(!)

/GI
8P (!) GIH +  I
=
(!)
/@
=
>

(4.13)

The full system of MOM equations is given by plugging in 8 = 0,1, … ,5 into (4.13):
(!)

(!)

(!)
/G v/@ =  °=>

(4.14)
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(!)

(!)

(!)
(!)
/GH v/@ = wP (!) G +   °=>
(!)

(!)

(!)
(!)
/Gf v/@ = w2P (!) GH +  f °=>
(!)

(!)

(!)

(!)

(!)

(!)

(!)

(!)

(!)

(!)

/G v/@ = w3P (!) Gf +   °=>
/G v/@ = w4P (!) G +   °=>
(!)
(!)
/G± v/@ = w5P (!) G +  ± °=>
(!)

(!)

/ (!) v/@ = −3K& 86 P (!) Gf °=>

This set of equations provides the steady state moment model of the MSMA-PFC. This
technique permits rapid solution in terms of moments, but loses the full CSD. The MOM
requires computationally much cheaper function evaluations, making it more efficient in
the optimization which requires multiple iterations within the genetic algorithm. These
seven equations solve for two important average quantities at the exit of the MSMA-PFC.
The exit ( = ) mass-mean crystal size is given by:
()

()

  = G °G

(4.15)

and the exit mass-mean coefficient of variation is given by:
  = ²G± G °(G )f − 1
() ()

()

(4.16)

The first six moments (0 through 5) were solved for, since these are required to fully
calculate (4.15) and (4.16).

The main drawback to this approach is that knowledge of the full CSD is lost during the
transformation. Theoretically, one can reconstruct a CSD by solution of a Q × Q linear
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system, where Q is the number of bins in the reconstructed CSD. There can be substantial
numerical difficulty in calculating moments of very high order, since the calculation
requires the number of moment equations to be equal to (Q − 1). Figure 2 in McGraw

[178] shows increasing deviation from the exact solution for increasing 8, for the case of

GH through G± . Also, this Q × Q system is typically ill-conditioned, meaning that even
slight changes in the matrix elements can dramatically change the uncovered CSD [111].
The method also cannot be used when the lower moments are functions of higher ones solution becomes impossible since closure of the equations is never attained. This
“closure problem” occurs when more complicated terms are used for the modeling of
growth, breakage, and agglomeration [182]. For this reason, simplistic terms for growth,
such as constant or linear size-dependence, are commonly used in the literature – and also
why breakage and agglomeration are typically neglected.

However, other methods can circumvent this problem and allow us to solve for the full
CSD. Various solution approaches are available to solve the PBEs for the full CSD, such
as the high resolution finite volume (FV) technique [113], [173], [174], weighted
essentially nonoscillatory (WENO) [183], [184], finite element method (FEM) [185],
[186], method of characteristics (MOCH) [183], [187], Lattice-Boltzmann method (LBM)
[188], [189], and Monte Carlo method[190], [191]. In this work the PBEs were solved
using a high resolution FV technique, which is the combination of the semi-discrete FV
technique with the van Leer flux limiter, for its efficiency and ease of implementation
[113], [173], [174]. The method discretizes (2.13) into Q ordinary differential equations,
where Q is the number of crystal size bins. The discretization started at 2 µm, and
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progressed upward in 4 µm increments, for 249 additional increments, up to the
maximum bin size of 998 µm, for a total of 250 bins. Just as in the MOM case, the mass
balance equation (4.6) is also solved. This technique can capture the sharp front without
numerical oscillations and provides at least second-order accuracy where the solution is
smooth.

To summarize the two solution methods, the MOM method entails solving 7
simultaneous ODE’s, while the FV method requires solving 251 . The greater speed
(about 1/16th the wall-clock time of the FV method) of the MOM method makes it more
appropriate for solving the optimization problems. The moment-transformed equations
were solved using MATLAB’s ‘ode23’ solver, while the FV equations were solved using
Runge-Kutta numerical integration (‘ode45’ in MATLAB). In our approach we used the
fast MOM method with the genetic algorithm to decrease the computation time for
finding the optimal antisolvent profiles and crystallizer design, and then used the FV
method to observe the full CSD for selected antisolvent profiles.

4.4.3

Multi-Objective Optimization Problem Formulation

The multiobjective problem formulation follows that given in section 2.8.1. With regards
to our system,  and  are strong functions of the antisolvent flowrate vector, X, and

manipulating Xiwill change Y. While there are some instances in which small crystals are
desired (e.g. inhalable powders and injectable drugs[21]), we generally desire a narrow
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CSD (low ) with a large mean size (highi ). To solve the MOO problem, we used
MATLAB’s implementation of the non-dominated sorting genetic algorithm (NSGA-II),
‘gamultiobj’, to search over X for the non-dominated set, since it is found to work well
for solving similar type of optimization problems[146], [192]. For eachiX, the model
equations discussed in the previous section were solved. The final result from the last
crystallizer segment was used to calculate the objective function values.  and  for

:(, @#0% ) were calculated using:



Y = ³1/  ii  ´ ,

(4.17)

where 1/  i is used because `gamultiobj’ seeks to minimize functions. The actual
decision variables used in the optimization were fractions of a required total antisolvent
flowrate:
! = =!  i,

(4.18)

where = is the decision variable manipulated by the genetic algorithm for the jth

crystallizer segment, and  is the total required antisolvent flowrate. An equality
constraint forced these percentages to sum to 1:
µ =! i = 1

(4.19)

!

Each individual decision variable was also bounded between 0 and 1:
0 ≤ =! ≤ 1

(4.20)
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4.5
4.5.1

Results and Discussion

Nonconvexity of  and CV Landscapes

For the solution of the optimization problem both gradient-based and stochastic (GA)
algorithms were investigated. Derivative-based algorithms generally offer much faster
convergence when the objective function is smooth and convex or with relatively small
number of local optima. When this is not the case however, stochastic methods are more
appropriate, since such methods are more robust to poor initial guesses. A numerical
analysis was performed to investigate the nature of the optimization problem to
understand why the GA appeared to be more appropriate. To do this, we performed bruteforce evaluation over the antisolvent profiles of  i and  for two injections, and
plotted the responses. The crystallizer modeled using this approach used all the same
parameters as in Alvarez and Myerson[169]. Missing sections of these plots denote an
infeasible crystallization due to a negative supersaturation.
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Figure 4.2 L43 and  response surfaces for two injections. The landscapes (a) and (b)
present nonconvexity that makes gradient optimization difficult. Great sensitivity to
antisolvent flowrate is observed. The contour plots (c) and (d) are zoomed closer to the
extrema for clarity.

Figure 4.2 shows the response surface for two injections. The nonconvexity we believe is
due to the system, taken as a whole, alternating between nucleation-dominant and
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growth-dominant regimes along the length of the array. We further remark that the
objective landscape appears highly sensitive around some of the extreme points. The
maximum  i (80.2 µm, black arrow, Figure 4.2c), rests at the crest of a tall, knife-like
ridge. This indicates that the optimal  is highly sensitive to model or implementation

uncertainties. Small deviation in flow rate A2 would greatly reduce the mean size of the
actually obtained CSD. Furthermore, deviations in the crystallization kinetic parameters
from the nominal values are also likely to lead to large deviations from the theoretically
optimal performance. An analogous problem exists in the  landscape, where we can

see that global minimum and global maximum are in close proximity. The  global

minimum (0.195, white text, Figure 4.2d) lies in a narrow valley behind the sharp crest
containing the  global maximum (0.351, black arrow, Figure 4.2d). Any error in A2
will fail to realize the global minimum .

4.5.2

Multi-Objective Optimization Results

In this section, different sets of kinetic parameters are used to generate the Pareto
frontiers calculated by the NSGA-II algorithm. The motivation for analyzing this
sensitivity lies in the fact that there can be appreciable uncertainty involved in the
estimation of the kinetic parameters and as such it is a good idea to investigate the impact
of these uncertainties on the crystallizer performance. These results are for a fourinjection PFC array, with the same dimensions and flowrates as given by Alvarez and
Myerson[169]. The total antisolvent flow rate was constrained to be 200 ml/min. The
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obtained results are shown in Figure 4, where the default case is for 9 = 7 = 1 .
Altering the kinetic parameters (89 and 87 ) by ±50% affected the position of the Pareto

front. The results indicate small sensitivity in the realized CV, though  shows higher

sensitivity. The genetic algorithm used a population size of 100, and was permitted to run
for a maximum of 500 generations, though on average finished after about 165
generations. In summary, for about 50% error in the kinetic parameters manipulated, little
change can be observed in , and  i varies by about ±2.5 µm, which is also relatively
small, indicating that the conclusions of the approach are relatively robust to variations in
the model parameters. We wish to emphasize here that the parameters were manipulated
prior to optimization, and thus these results indicate the sensitivity of the optimization to
shifts in the kinetic parameters.

Coefficient of Variation, CV [nd]
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Figure 4.3 Pareto frontier plots for four injections ( vs. L43) and different sets of
kinetic rate parameters, kb and kg. The ’s in the legend correspond to multipliers of the
base case, e.g. γb = kb’/ kb. The base case corresponds to γb = 1 and γg = 1, with kb = 1.3 x
108 #/(m3·s), and kg = 9.9 x 10-7 m/s. We observe that there is some sensitivity with
respect to these parameters on the Pareto frontier, but mainly the effect appears in L43.
Little shift is seen in the realized coefficients of variation. For clarity, only the final 25
generations of each parameter set are plotted. The black arrow (L43 = 89.98 µm,  =
0.20) is a representative point that is referred to in Figure 4.4, Figure 4.5, and Figure 4.6.

4.5.3

Investigation Into the Sensitivity to Kinetic Parameters

In the reverse case, we have chosen a representative point from Figure 4.3 (the black
arrow), and varied the kinetic parameters by ±50% after the optimization has been
performed (Figure 4.4). This gives us an idea of how sensitive the solutions themselves
are to error in the kinetic parameters. As expected,  increases with the increase of 87

and decreases with the increase of 89 . Counter-intuitively, we see that  decreases as

89 increases. We expected higher nucleation produce more fine crystals, thus increasing

. To determine why this is, the finite-volume solver was used to plot the volume
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fraction distributions of crystals at the three numerical labels in Figure 4.4b. These
distributions are shown in Figure 4.5. It is observed that the mean size does indeed
decrease with increasing 89 . However,  slightly decreases due to the elimination of the
second mode (the smaller hump in the blue curve in Figure 4.5). It appears that a higher
89 reduces the ability of growth processes to spread out the distribution. This is because a
total antisolvent of 200 ml/min was used, thus “locking in” the total available
supersaturation. Higher nucleation consumes more of this available supersaturation,
leaving less available for growth. Thus we see a narrowing of the distribution due to
having a tighter group of fines created during the crystallization.

(a)

(b)

Figure 4.4: Variation in L43 and CV for the representative chosen point. Significant
sensitivity is observed with respect to kg. Copyright 2014 IEEE.
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Figure 4.5: Volume size distributions of crystals as a function of nucleation rate constant,
kb. It is observed that increasing kb decreases the mean size (approximately the mode), but
shape-wise the peaks are isomorphic. The second mode in the blue curve is eliminated
with increasing nucleation rate.

4.5.4

Comparison between Heuristic Antisolvent Profiles and Rigorous Optimization

Alvarez and Myerson [169] experimented with splitting 200 ml/min antisolvent equally
over 1, 2, 3, and 4 injection points in the PFC array, and observed the effect on the
volume size distribution. We show that rigorous optimization of antisolvent profile
predicts a better result. Referring to the black arrow in Figure 4.3, we have selected a
representative point from the Pareto front of the nominal case ( = 89.98 µm,  =
0.20), which uses the original set of kinetic parameters (89 = 1.3 × 10© #/(m3·s), and

87 = 9.9 × i 10¨ m/s). Numerical values of the antisolvent flowrates for each of these
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cases are given in Table 6. Plugging these profiles into the finite-volume solver generates
the volume size distributions shown in Figure 4.6.

Figure 4.6: Volume fraction distributions of crystals for 1, 2, 3, and 4 equal-flow
injections, and the optimal 4-injection profile of the antisolvent. In the 1, 2, 3, and 4
injection plots, 200 ml/min of antisolvent is split equally a corresponding number of ways
among the injections. The optimal result uses the flows taken from the representative
point (Figure 4.2, black arrow).

The corresponding antisolvent profiles are listed in Table 2. The optimization has left CV
essentially the same, but has substantially increased  . The optimal profile is different
from equal apportionment of antisolvent. The optimal antisolvent addition profile is such
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that at the first segment about 30% of the total antisolvent is added which generates
enough supersaturation so that nucleation occurs. At the second segment almost no
antisolvent is added so that the crystals from the first segment can grow in moderate
supersaturation without further nucleation. In the subsequent two segments the remaining
30% and 40% of the total antisolvent is added to facilitate the further growth of the
crystals.

Table 6 Antisolvent flow profiles used to generate the crystal volume size distributions
shown in Figure 4.6 and the corresponding performance index.
Performance
Flow in injection port (ml/min)
index
Cases
·¸¹
1
2
3
4
CV
(µm)
1

200

×

×

×

64.47

0.21

2

100

100

×

×

70.8

0.21

3

66.7

66.7

66.7

×

83.25

0.21

4

50

50

50

50

70.35

0.21

Optimal

59.9

1.22

57.72

81.02

92.05

0.21
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It is interesting to note that the 4 equal injections case in Figure 4.6 is inferior to the 3
equal injections case, which disrupts the trend demonstrated from the  sizes produced
from the preceding three cases. To understand the cause of this, observe the plot of
concentration versus external length in Figure 4.7. It can be seen that in the 4-injection
case, the operating point after the first injection is in the first segment is below the
solubility curve, and thus the antisolvent addition generates no supersaturation, hence the
first segment having no contribution to the crystallization process. In the second segment
the crystallization is operated in the metastable zone, but without the first segment the
total residence time available for the crystal growth after crystals can form is shorter than
in the other cases, therefore crystals cannot grow to larger sizes. Since during antisolvent
addition, the concentration in the system decreases due to the dilution effect
simultaneously with the decrease in solubility, this dilution effect has to be taken into
account to make sure that enough antisolvent is added in the system to reach
supersaturation. In the case of the 3 equal injections, the first PFC segment already
operates in the metastable zone, yielding nucleation and then growth in the rest of the
length of the PFC. In the optimal case, it appears the best procedure is to generate a
moderate supersaturation initially, and then quickly reduce it to a lower level. The likely
interpretation of this result is that initially supersaturation is desired to be relatively high,
encouraging nucleation as soon as possible so that there will be enough residence time for
growth. Once sufficient crystals have been generated, lower supersaturation would then
foster growth. The single addition generates very high supersaturation immediately
promoting excessive nucleation in the system, whereas the two equal injection generates
higher supersaturation than what is achieved in the second segment of the four additions
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case, following a relatively similar operating curve in the phase diagram. This is in
correlation with the results in Figure 4.6, which show that the final CSDs are similar for
the 2 and 4 equal injection cases, with more pronounced nucleation in the latter case.

Figure 4.7 Concentration vs. external length plot for equal splits of total antisolvent
across one, two, three, or four sections. The optimal result from the representative point is
the "Optimal" line. Dotted lines are the concentration in the crystallizer. Solid lines are
solubility concentrations.
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4.5.5

Investigation of Design Robustness with Regards to Antisolvent Flowrate Error

In optimization and control practice optimal solutions are often sensitive to parametric
and/or control variable uncertainty. It is important to know the robustness limits
especially for equipment with the production of pharmaceuticals in mind, as designs with
high variability are counterproductive to implementing QbD. In this section, we have
investigated the sensitivity of the previous optimal profile to uncertainty in the
antisolvent flow profile. We are especially interested in flow profile robustness, since the
results in Figure 4.2 suggest there is great sensitivity to error in antisolvent flowrates.
Error was simulated in the process by a simple Monte-Carlo simulation. Using the same
optimal flow profile from Table II, random samples were taken from the nominal values
over a range of ±50%. These ranges are listed in Table 7 below.

Table 7 Flowrate Uncertainty Bounds For Robustness Analysis
Nominal
Low
High
Segment
(ml/min)
(-50%) (+50%)
1

59.90

29.95

89.85

2

1.22

0.61

1.83

3

57.72

28.86

86.58

4

81.02

40.51

121.53
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The first robustness simulation only permitted error in a single segment in the entire
apparatus. 104 trials each were done for each of the four flowrates. After a random flow
vector was chosen, the MOM solver was used to solve for  and , and the results
presented as scatterplots. The results for varying a single flowrate are shown in Figure 4.8
below. The red dot corresponds to the nominal (zero-error) case. Figure 4.8 clearly shows
that uncertainty of flow in the first stage has the most impact on the process. The
scatterplot has traced out a wide envelope of points that resemble a continuous curve. The
uncertainty in subsequent flows is ineffectual, as the scatter plot of points have all hardly
budged from the nominal point.
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Figure 4.8 Robustness analyses with respect to flowrate by varying a single flowrate. The
Roman numerals correspond to the particular MSMA-PFC segment for which random
antisolvent flows are being sampled by the simulation. The red dot is the result for the
nominal (zero-error) case. Copyright 2014 IEEE.

We further examined the effect of error in multiple simultaneous stages, by permitting the
same level of variation, but also varying the stages cumulatively. Figure 4.9 below shows
these results for 104 trials in each case.
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Figure 4.9 Robustness analyses for multiple varying flowrates. The Roman numerals
refer to which stage, and all others preceding it, are being sampled by the simulation. The
red dot is the result for the nominal (zero-error) case. Copyright 2014 IEEE.

Stage II imparts only mild change in the response, which is likely due to the small
flowrate. However, significant variation is observed when stage III is reached, and many
new points are reachable that are not present in Figure 4.8. Figure 4.9 suggests that the
first stage, where primary nucleation occurs, is by far the most sensitive segment.
Furthermore, the increase in nucleation in stage III also makes the process sensitive to the
flowrate into that segment.
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4.6

Summary and Conclusions Regarding Flufenamic Acid Optimization Work

The chapter describes a multi-segment multi-addition continuous plug flow antisolvent
crystallization (MSMA-PFC) setup. We utilized an integrated simulation and
optimization framework to analyze the performance and robustness of the MSMA-PFC.
The population balance model of the MSMA-PFC was introduced, which was solved,
depending on circumstance, with either the method of moments, or the finite-volume
method. The model was used in a model-based multi-objective optimization framework
to design optimal antisolvent addition policies that maximize mean size and minimize
coefficient of variation, using a genetic algorithm for global optimization and to compute
the Pareto frontiers, which were also analyzed in the case of uncertainties in the model
parameters. Concerning the robustness analysis of the antisolvent flowrates, it appears the
proper control of nucleation will have significant process impact, and that uncertainty in
antisolvent

flowrate

will

drastically

affect

performance

wherever

nucleation

predominates over crystal growth. We also conclude that error is best treated by
considering the flow profile as a whole, since there appears to be significant interaction
between how the upstream stage impacts the downstream performance – a known issue in
the subject of continuous pharmaceutical manufacture and process design in general.
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CHAPTER 5. SIMULTANEOUS DESIGN AND CONTROL OF THE MSMA-PFC

5.1

Abstract

We have investigated the simultaneous design and control (SDC) of the MSMA-PFC.
The SDC framework allows us to optimize not only over flowrates, but over the
crystallizer geometry as well. By use of rigorous modeling and optimization, we solve a
combined design and control problem to find superior crystallizer designs with
corresponding optimal operating conditions for the MSMA-PFC. The procedure works
by optimizing the MSMA-PFC crystallizer for various 2-tuples of total length and
number of injections. In the first part of this study, we revisit the flufenamic acid
optimization discussed in CHAPTER 4. The results indicate greater mean crystal sizes
are attainable using the SDC approach. We then repeat this same analysis, but now also
have feed flowrate and total antisolvent flowrate as decision variables. For both cases we
examine the results derived by either maximizing the mass-mean crystal size, or
minimizing the coefficient of variation. The results are plotted as landscapes with the
number of injections and the total length as the independent variables. When feed and
total antisolvent flowrate are used as decision variables, generally higher feed flowrates
are observed when minimizing . There is little difference between the landscapes of
total antisolvent addition. The residence time landscapes show that the optimal residence
time is (roughly) a linear function of total length, and is independent of the number of
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injections. Plots of the crystal size distributions show that minimization of  leads to a
much smoother crystal size distribution, albeit with much lower mean size. We
investigated in greater depth the maximum case of 25 injections. Here, maximization of
 leads to more complicated multimodal distributions. This is likely due to the
calculation of  being heavily biased towards larger crystal sizes. When total flowrates

are used as decision variables, the antisolvent addition profiles for the two cases do not
exhibit any distinct patterns or cycling action as was seen previously when they were not
used as decision variables. Antisolvent addition is always widely distributed across the
length of the crystallizer, indicating that better results are obtained by lengthwisedistribution versus using a single addition at the beginning of a single tube. Adjustment
of total length does not reveal any patterns in the antisolvent addition profiles. The
growth and nucleation rate profiles show that most of the growth and nucleation take
place in the first half of the crystallizer, and that nucleation and growth rates decline
toward the end. There is significant differences between the growth and nucleation rate
profiles obtained for different tube lengths.

5.2

Simultaneous Design and Control (SDC) Framework for the MSMA-PFC with
Static Feed Flowrate and Static Total Antisolvent Flowrate

We examined a new type of optimization problem for the MSMA-PFC, in terms of not
only the antisolvent profile, but the number of injections and the total crystallizer length
as well. This problem is a simultaneous design and optimal control (SDC) formulation
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that aims to provide the best MSMA-PFC design which can provide the overall best
performance under optimal operating conditions. This problem leads to a more
complicated mixed-integer nonlinear programming problem (MINLP) [193], [194], since
the decision variables consist of a set of discrete variables (total length and number of
injections), as well as a set of continuous variables (the individual antisolvent flowrates).
The complexity of the SDC problem necessitates a single-objective approach. Figure 5.1
presents a flowchart that explains the method used, with the following steps:
1. To optimize the PFC array, an initial total length was assumed, @ .
2. As shown in (4.4), this length is cut into progressively smaller fractional subsegments of equal length. Antisolvent is injected at the beginning of each
segment, just like in (4.4).
3. For each of these injection sub-cases, the single-objective genetic algorithm
manipulates the antisolvent flowrates into each segment in order to either
maximize the  crystal size at the exit, or minimize  at exit.

4. After a maximum number of injections are iterated over (15 in this case), @º»º¼½
is increased, and the process begins anew.
5. The loop continues until the last injection the final @ is reached. The
outputs of these optimizations generate landscapes of  , , and yield.

Yield was calculated according to the equation:
R=

0 ##% − (##% + 
  )0
.
0 

(5.1)
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The MOM was used to speed up the solution of the model equations called by the
genetic algorithm. Total antisolvent flow was constrained to be equal to 200 ml/min (the
original value from CHAPTER 4), and the decision variables used by the GA were
percentages of this amount (constrained to sum to 100%). The feed flowrate was kept
static at 100 ml/min (again, the same value used in CHAPTER 4). An initial population
of percentages was used for each start of the genetic algorithm, drawn randomly and
made to satisfy this constraint. The population size scaled up with the problem size
according to 100 + 25 , where

is the number of injections for the current problem

being solved by the GA. A maximum of 200 generations was used. All other solubility
and kinetic parameters were kept the same as in Alvarez and Myerson[169]. At the
conclusion of the optimization, the  icrystal size, , and yield were calculated and
stored for later plotting. The total length began at 10 meters, and was increased in 10
meter increments to 50 meters. The number of injections began at 2, and was increased in
the inner loop to 15 maximum injections.
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xsegment = xtotal/2

Injections = 2
Injections = 3

xsegment = xtotal/3

...

xsegment = xtotal/n

Minimize objective
using genetic
algorithm for each
injection case

START

NO
Increase xtotal

xtotal > xfinal?
YES
Terminate

Figure 5.1 Flowchart for the simultaneous design and control (SDC) optimization of the
MSMA-PFC array. The algorithm proceeds by cutting a PFC array of a given total length
into progressively smaller subunits. Genetic algorithm optimization is performed on each
case.

5.3

Results for Simultaneous Design and Control (SDC) Optimization with Feed
Flowrate and Antisolvent Flowrate Kept Static
5.3.1

Landscape Plots of Total Length vs. Number of Injections

Figure 5.2 shows the results for the simultaneous design and control (SDC) optimization
of the entire MSMA-PFC array. Generally, as expected we observe larger crystal sizes
with increasing total crystallizer length, due to longer residence time. The number of
injections does not appear to make much difference in  past about 5 injections.

However, in Figure 5.2b, increasing the number of injections tends to reduce  further.

Figure 5.2c confirms that the yield is virtually identical in all cases, always achieving a
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value of about 93%. This result stems from the fact that the total flow of antisolvent is
fixed for all cases, inferentially controlling the overall yield of the MSMA-PFC.

(a)

(b)

(c)

Figure 5.2: Results of the simultaneous design and control (SDC) optimization
framework for the MSMA-PFC array over length, number of injections, and antisolvent
profile, showing (a) the L43 crystal size, (b) coefficient of variation (CV), and (c) the solid
crystal yield computed via equation (5.1).

5.3.2

Further Investigation of the Maximum Obtained L43 and Minimum Obtained CV

The maximum obtained  size was 135 µm at @ = i50 meters and 11 injections.
The  for that point was 0.24. The minimum  was 0.207, obtained at @ = i20

meters and 14 injections. The  for that point was 114 µm. These points are explored in
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greater detail in Figure 5.3. Figure 5.3a shows the volume CSD’s for these two points.
We can see the multimodal nature in the '>
 distribution, which is indicative of some
cyclic behavior in the process. This behavior is not present in the  '0 volume

distribution. The explanation for this is seen in Figure 5.3b, which shows the antisolvent
profiles. We can see the optimal profile for maximizing  produces a cyclic-type
“bursting” of antisolvent. Physically, we interpret this as the optimization seeking to
avoid unnecessary nucleation, and focus on growing a smaller number of crystals that
were nucleated near the beginnings. On the other hand, the  '0 antisolvent profile
indicates that most of the antisolvent is added in the second half to minimize variation in
the size. In the former case the operation is characterized by a more aggressive nucleation
generation in the initial part of the crystallizer to favor the formation of crystals as soon
as possible maximizing the residence time available for growth, whereas in the latter the
minimization of the  requires more gentle nucleation control at the beginning to
minimize the multi-modal nature of the CSD, and then gradual increase of the
supersaturation. The results indicate that for optimal performance equipment should be
designed to allow the implementation of the appropriate optimal control strategy
depending on the objectives. Future continuous crystallizers therefore need to be
designed to be flexible, reconfigurable and adaptable to allow optimal operation. This can
be achieved by adopting the proposed SDC framework.
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(a)

(b)

Figure 5.3: Results for SDC over total length, number of injections, and antisolvent
profile. We have chosen two points from the surfaces in Figure 5.2 for examination – one
point corresponding to the maximum obtained L43, and the other corresponding to the
minimum obtained . (a) shows the volume CSD’s for these two points. The antisolvent
profiles that produced these distributions are shown in (b).

5.4

Problem Formulation for Case When Total Flowrates are Used as Decision
Variables

In the prior results discussed in section 5.3, we used a fixed total antisolvent flowrate and
a fixed feed volumetric flowrate. In the results in this section, these strictures have been
removed and total antisolvent ( , ml/min) and feed flowrate (##% , ml/min) have
become bounded decision variables. Much like in section 5.3, we have investigated how
the results change whether the objective is to maximize  or the minimize  .
Landscapes were generated for various quantities of interest by iterating over total
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MSMA-PFC length and the number of injections. The model equations, parameters, and
solution methods are identical to those in CHAPTER 4. The two optimization problems
solved independently (not multi-objective) were:
i

.@
.! , ##% , 



(5.2)

:
.! , ##% , 



(5.3)

and
i
Both of which were subject to:
10 ≤ ##% ≤ 1000
10 ≤  ≤ 1000
0 ≤ .! ≤ 1
i



µ .! = 1
H

(5.4)


≤0
0 − 1.050

−0 + 0
≤0

The prior SDC results did not require a yield constraint, as using a fixed quantity of 200
ml/min antisolvent with 100 ml/min of feed would “lock-in” the final yield. However,
with ##% and  now free decision variables, a constraint on yield is now require to
remove economically infeasible designs from consideration.
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5.5

Results and Discussion for Case When Antisolvent Flowrate and Feed Flowrate are
Decision Variables
5.5.1

(a)

Landscapes for Feed Flowrate

(b)

Figure 5.4 Optimized landscapes of feed volumetric flowrates (Vfeed) against total length
of PFC array and number of PFC injections. In (a) the objective was to maximize L43. In
(b) the objective was to minimize .

The results in Figure 5.4 are the optimal values of ##% for various ordered pairs of total
length and numbers of injections. In this section and all of the succeeding sections in this
chapter, all data corresponding to the maximization of L is presented in red, and all data

corresponding to the minimization of CV is presented in blue. While these data are

somewhat noisy due to the use of the GA, some trends can be noticed. First, we observe
that the optimal values of ##% in both cases are generally higher than 100 ml/min,
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suggesting longer arrays with more injections can handle a higher mass throughput. We
furthermore see that the flowrates tend to be higher when minimizing .

5.5.2

(a)

Landscapes for Total Antisolvent Flowrate

(b)

Figure 5.5 Optimized landscapes of total antisolvent volumetric flowrates (Atotal) against
total length of PFC array and number of PFC injections. In (a) the objective was to
maximize L43. In (b) the objective was to minimize .

Figure 5.5 shows the optimal values of  for the two optimization problems. These
results however, are much closer to one another than the previous plot. A general trend
we observe is that longer arrays tend to use more antisolvent than shorter ones. The
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similarity in shape may be due to the fact that both optimizations are subjected to the
same yield constraint. Thus, a higher feed flowrate would demand a higher antisolvent
flowrate in order to deplete the supersaturation to within feasibility. This suggests that the
distribution of the antisolvent impacts the process more subtly, though importantly.

5.5.3

(a)

Landscapes for Residence Time

(b)

Figure 5.6 Optimized landscapes of residence time ( ) against total length of PFC array
and number of PFC injections. In (a) the objective was to maximize L43. In (b) the
objective was to minimize .

Figure 5.6 shows the residence time landscapes. We can conclude than that optimal
residence times follows a roughly linear trend with increasing total length, and is
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independent of the number of injections. The similarity between the two plots suggests
that total residence time is not precisely what differentiates the two control strategies
arrived at by the optimization, and that the individual flowrates are much more important.
The relative independence of residence time with the number of injections suggests that
the optimal residence time is determined more by the yield constraint and tube geometry,
rather than the individual flowrates of antisolvent or the feed flowrate.

5.5.4

Landscapes for Mass-Mean Crystal Size and Coefficient of Variation

(a)

(b)

Figure 5.7 Optimized landscapes of mass-mean crystal size (L43) against total length of
PFC array and number of PFC injections. In (a) the objective was to maximize L43. In (b)
the objective was to minimize .
Figure 5.7 shows the landscapes for mass-mean crystal size. Clearly, maximizing 

leads to much larger crystals than when minimizing . These results are in agreement

132
with the Pareto frontier results from section 4.5.2, which show that there is a significant
tradeoff between these two quantities during optimization. We furthermore note that there
is not much increase in the maximum obtained crystal size (about 140 µm) compared to
the 135 µm in Figure 5.3. The landscapes for coefficient of variation are shown in Figure
5.8 below are somewhat puzzling in that the results in Figure 5.8a show generally lower
 than those in Figure 5.8b. This may be due to the greater complexity of the 
objective function causing improper convergence, as evidence by the landscape plot in
section 4.5.1. However, certain points do show significantly higher  when solely

attempting to minimize  , suggesting again that a more aggressive crystallization leads
to more growth, but also more nucleation.
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(a)

(b)

Figure 5.8 Optimized landscapes of coefficient of variation () against total length of
PFC array and number of PFC injections. In (a) the objective was to maximize L43. In (b)
the objective was to minimize .

5.5.5

Number Fraction Distributions for the Case of 25 Injections

Figure 5.9 shows the final exit distributions calculate using the finite-volume method for
the case of 25 injections for the crystallizer lengths of 1 meter and 50 meters. The two
distributions in each graph correspond to either attempting to maximize  , or minimize
. We can see in Figure 5.9 two main features that stand out from this data. Maximizing

 tends to lead to a multimodal distribution (Figure 5.9a red curve). This is because the

objective was to maximize  , and  the calculation of  is dominated by larger
crystal sizes. The distributions generated from minimizing  are much smoother, and do
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not tend to be multi-modal. We observe though the longest tube length of 50 meters, the
multiple modes in the red curve die out.

(a)

(b)

Figure 5.9 Number fraction distributions for the case of 25 injections. Each plot
corresponds to a different total length. (a) 1 meter and (b) 50 meters.
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5.5.6

Antisolvent Profiles for the Case of 25 Injections
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(b)

Figure 5.10 Antisolvent fraction profiles for the case of 25 injections. Each plot
corresponds to a different total length. (a) 1 meter, (b) 50 meters.

Figure 5.10 above shows the antisolvent fraction profiles for the two optimization cases.
Generally, it is difficult to discern noticeable features from these profiles, indicating that
optimal or near-optimal solutions are not intuitive. Nearly all addition used less than 10%
of the total antisolvent. The profiles are different from each other, agreeing with intuition
that total length is a significant design variable that directly impacts the optimal possible
performance, and also affects what the antisolvent addition profile should be.
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5.5.7

Growth and Nucleation Profiles for the Case of 25-Injections

Figure 5.11 shows growth and nucleation rate profiles for the case of 1 meter and 50
meters total length when maximizing the mean crystal size. Figure 5.12 likewise shows
the same type of figures for those same lengths, but for the case of minimizing the
coefficient of variation.
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Figure 5.11 Growth and nucleation rate profiles for the case of maximizing mass-mean
crystal size. (a) 1 m total length, (b) 50 m total length.

137

4

2

10

0

0

0.2

0.4
0.6
0.8
External Length, x [m]

(a)

1

0

Min CV, xtotal = 50 m
400

x 10
4

crash
crystallization

200

2

0

0
0

12

Nucleation Rate, B 0 [#/m3⋅ s]

20

10

Growth Rate, G [µ m/s]

30

x 10
6

Nucleation Rate, B 0 [#/m3⋅ s]

Growth Rate, G [µ m/s]

Min CV, xtotal = 1 m

0.2
0.4
0.6
External Length, x [m]

(b)

Figure 5.12 Growth and nucleation rate profiles for the case of minimizing coefficient of
variation. (a) 1 m total length, (b) 50 m total length. Note the change of x-scale in (b).

For the case of maximizing mean size, generally, the optimization seeks to raise the
growth and nucleation rates in a pulsing fashion. However, two of the plots show
exception to this rule. Figure 5.12a shows a distinct “jagged hill” type profile which is
not seen in any of the other plots. It is also worth noting that this profile scored a much
lower  than was typical (about 0.08) in Figure 5.8b. This suggests that many small
segments are required to exert effective control over the fast-acting process of nucleation.
Figure 5.12b shows that virtually all of the growth and nucleation occur in the first stage
as a crash crystallization. Intuitively, growth and nucleation decline toward the end of the
crystallizer. This is partly in order to satisfy the yield constraint, but also because
available supersaturation is being consumed by growth and nucleation.
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5.6

Summary and Conclusions

A simultaneous design and control (SDC) framework is proposed based on the complete
optimization of the entire PFC array over total length, number of injections, feed flowrate,
total antisolvent flowrate, and antisolvent profile. It is shown that, for the case of static
feed and antisolvent flowrates, the typical optimal antisolvent addition protocol leads to a
cyclic operation which promotes shifts between growth-dominated and nucleationdominated regimes in the different PFC segments. This periodic operation yields to a
strongly nonconvex search landscape motivating the use of genetic algorithm for the
optimization. We have also investigated the performance of the MSMA-PFC when feed
flowrate and total antisolvent flowrate are used as decision variables as well. The results
indicate that there is little increase in maximum  crystal size compared to the results in
CHAPTER 4, though significantly lower CV’s can be obtained. However, higher
flowrates are obtained by the optimization, indicating a higher mass flowrate can be used
without reducing the mean size. The flow profiles have no discernible pattern, but do
indicate that there is benefit to distributing antisolvent across the length of the crystallizer.
The growth and nucleation rate profile plots indicate, for both optimizations, a general
pattern of high supersaturation at the beginning of the crystallizer, with supersaturation
being “pulsed” down the remainder of the length of the crystallizer. The SDC framework
can be used to design flexible, reconfigurable and adaptive continuous crystallization
systems that can achieve optimal performance by allowing the implementation of the best
control strategy needed for a particular objective and under certain operating constraints.
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CHAPTER 6. PARAMETRIC STUDY OF THE FEASIBILITY OF IN-SITU FINES
DISSOLUTION IN THE MSMA-PFC

6.1

Abstract

We have investigated the use of an antisolvent MSMA-PFC , which can grow and keep
extant large crystals while dissolving fines in-situ. By applying and extending the
framework discussed in CHAPTER 5, we have shown that dissolution is rejected by the
optimization and that dissolution is suboptimal. A reduced orthogonal array experimental
design was used to avoid a high computation time. The results of the main-factor analysis
show that nucleation rate imparts the greatest process sensitivity, followed by growth rate.
High nucleation overwhelms the MSMA-PFC. The MSMA-PFC performs best under
kinetic crystallization conditions in which a single PFC also works sufficiently well,
indicating little benefit.

6.2

Introduction

While purification is the main motive behind crystallization, the crystal size distribution
(CSD) affects downstream operations and the ameliorative properties of the final dosage
form. Downstream processes affected by CSD shape include filtering, washing, and
drying [53]. The presence of fine crystals encumbers these operations.
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The curative properties of the final dosage form are dependent on the dissolution rate and
bioavailability, which are strongly affected by the CSD and other particle properties
[110], [195]. The typical method of removing fines is to classify the product crystals, redissolve the fines, separate the antisolvent when feasible, and recycle the mixture back to
the crystallization system. However, this method is problematic. Classification, recycle,
and stream separation require further process equipment, increasing capital and operating
costs. Classification combined with recycle has been mathematically deduced (and
subsequently observed) to impart oscillatory dynamics to the CSD. These oscillations
make it difficult to obtain a consistent product. Furthermore, from a risk analysis
viewpoint, extra equipment is generally “more things that can go wrong”, and present
another route by which microbes could contaminate the manufacturing process. Ideally, it
would be good if we could eliminate fines altogether by an in-situ approach.

6.3

Prior Work on In-Situ Fines Removal

Previous work by Abu Bakar et al. [195] and Majumder and Nagy [113] explored the
concept of “in-situ” fines removal, where the operation of the crystallizer actively
eliminates fine crystals during the crystallization by means of dissolution. With this
approach, classification, re-dissolving, and stream separation become (in theory)
unnecessary. The work by Majumder and Nagy [113] most closely follows our work here.
In that work, a constrained nonlinear optimization problem was solved to identify
operating curves that would match a target distribution in a least-squares sense by
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removing

fine

crystals.

Majumder

and

Nagy

[113]

previously

investigated

computationally the use of multisegment cooling crystallization for in-situ fines
dissolution. In that work, the decision variables were the jacket temperatures in each
segment, which allowed the particular segment to go above or below solubility as
necessary to dissolve the fine crystals and grow large ones. Ridder et al. [161], [162] have
modeled and optimized a multi-segment antisolvent crystallizer for drug crystal
production, but that work did not allow for dissolution to occur. This work is an
extension of the previous works by Ridder et al. and Majumder and Nagy, as we are now
using an antisolvent crystallization with the capability to dissolve crystals when below
solubility. Figure 6.1 below depicts the path of information flow for a cooling PFC
crystallization process, and an antisolvent PFC crystallization process. For an antisolvent
crystallization, the decision variables are the flowrates of antisolvent into each segment.
The cooling crystallization has no coupling between residence time and the control
(jacket temperature), and residence time is constant within each segment. None of this is
true in antisolvent crystallization, since the addition of antisolvent simultaneously affects
the current concentration via dilution, and reduces the current residence time due to a
mass balance argument. This coupling dramatically increases the difficulty in optimizing
the process.
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(a)

(b)

Figure 6.1 Information flow diagrams in a multisegment crystallizer for (a) cooling
crystallization and (b) antisolvent crystallization.

6.4

Parametric Study via Optimization of the Antisolvent Crystallizer

In this work, we present results for the steady-state operation of a multi-segment, multiaddition, plug-flow crystallizer MSMA-PFC which utilizes dissolution to eliminate fine
crystals. We have explored the geometric design parameters of the crystallizer, as well as
the kinetic parameters of crystallization. To reiterate, this work is an extension of that by
Majumder and Nagy [113], but for the case of antisolvent crystallization as opposed to a
cooling crystallization.
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6.5

Model Framework
water (solvent) streams, ml/min
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n1end
C1end

S2

SN

n2
C2

nN
CN

nNend
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N
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An

product

ethanol (antisolvent) streams, ml/min

Figure 6.2 Diagram of the MSMA-PFC. Seeded liquid solvent, with solute concentration
C0 flows in from the left into a mixing chamber (gray box). The dilution correction factor,
γj, is applied to the exit stream around each mixing point (red dashed boxes). The
combined streams then flow into a plug-flow segment (blue rectangle). Antisolvent
reduces solubility, triggering nucleation and growth. Streams of pure solvent are utilized
to push the solution below solubility when necessary.

The model presented here is similar to that discussed in CHAPTER 4 and CHAPTER 5.
Some important differences we mention immediately are:
•

The greatest difference is that the model now accepts pure solvent additions in
addition to antisolvent. The addition of pure solvent can permit the crystallization
to go below solubility, thus inducing dissolution of the crystals. The idea is to
dissolve the smallest crystals, while keeping the large ones relatively intact.

•

Before, ethanol was the solvent and water the antisolvent. In this chapter, water is
the solvent and ethanol is the antisolvent.

•

Flufenamic acid was the solute in the first model, whereas here we have no drug
in particular as the solute; this is a parametric study.
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•

In the prior model, concentration and number density were expressed on a volume
of solution basis. In this chapter, concentration and number density are based on a
mass of solution basis.

•

The prior model was unseeded, with primary nucleation present. Here we are
using a seeded process with secondary nucleation present.

The MSMA-PFC is based on the setup in Alvarez and Myerson [135]. It is modeled as a
series of ideal plug flow elements, of equal length, and antisolvent is added at the
beginning of each segment (Figure 6.2 above). Each of the N segments is a separate PFC,
running in steady-state, isothermal operation. The inlet stream (far left) feeds saturated
mother liquor at flowrate ##% (ml/min), with an initial concentration of solute,  (kg

API/kg solution), and a seed CSD, : (# of crystals/kg of solution∙m). At each mixing

point (gray boxes in Figure 6.2), antisolvent flowing at flowrate ! (ml/min), and pure
solvent at flowrate

!

(ml/min), for = 1,2, … , . We reiterate that we are using mass-

intensive units for our state variables, : (#/kg solution) and  (kg API/kg solution). After
mixing with the solvent and antisolvent streams, the mixture then flows into the

J

PFC

segment, where nucleation and growth occur. We assume the streams mix on a time scale
well below the induction time, and also attain plug-flow. At the exit of the segment, a
new size distribution, :(, @!#0% ) , and a reduced solute concentration, (@!#0% ) , are
obtained. We will abbreviate these quantities as :!#0% and !#0% . We clarify to the reader

that this is not the same as !£H or :!£H ; these quantities are created when the next solvent
and antisolvent streams are added; the pattern of indexing is made clear in Figure 6.2
above. This process continues recursively until the product stream leaves the final,
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#0%
 Ji segment (product stream). The final crystal size distribution, :
, is used for

#0%
solving the least-squares optimization problem. Both :
and #0% are used to calculate

several constraints. Summation indices always use the letter  as a dummy index. The
letter always refers to “for the

J

PFC segment.” When an index refers to a mixing

point, always refers to the mixing point immediately preceeding the

J

PFC segment

(e.g. thei = 1 mixing point is the very first mixing point on the left hand side in Figure
6.2 above).

The addition of streams ! and

!

to the process causes a decrease in  and : in the

oncoming feed stream due to the effect of dilution. Concentration and number density are
reduced is because the solute mass (and crystal mass) has remained the same, but total
volume has increased. There is a double meaning of this term in the literature, as some
authors refer to antisolvent crystallization as “dilution” [51]. We reiterate that in this
paper, we refer to dilution as being the reduction in solute concentration due to the
addition of liquid. To account for this effect, the number density of the

J

outgoing

stream, :! (# of crystals/kg of solution∙m) about the jth mixing point is multiplied by:
γ! = i

K!0 !0
0 0
K!£H
!£H

(6.1)

Where K!0 is the density of the solution, and ! is the volumetric flow rate of the
entire stream. ! can be determined by dividing the total solution mass flow rate by the

total solution density:
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0
!£H

=i

!

!

KÁÂ Ã ##% + H   + KÄÃÁ H  i
0
K!£H

(6.2)

Where KÁÂ Ã and KÄÃÁ are the densities of water and ethanol (997 kg/m3 and 785.22
0
(kg/m3), is calculated
kg/m3, respectively). The total solution density, K!£H

numerically from a curve fit of the density of an ethanol-water mixture in terms of
ethanol mass fraction. These expressions are derived by performing progressively wider
mass balances about the mixing points and PFC segments. The method is more easily
explained with a diagram (Figure 6.3 below). The colored boxes demonstrate the pattern
one follows to ultimately derive (6.1) and (6.2).

...

γ1

γ2

...

γN

Figure 6.3 Mass balance envelopes that are used to derive γ dilution correction factor.
Incoming streams are positive; outgoing are negative.

6.6

Crystal Population and Solute Mass Balance Equations

In order to properly model the crystallization, two equations need to be solved
simultaneously: the population balance equation, and the mass balance equation.
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The population balance equation is the same as (4.2). The mass balance on dissolved drug
is given by:
/!
K& 86
=−
(3PGf,! + ,!  )
/@
=>,!

(6.3)

The term Gf is the second moment of the crystal size distribution (m2 of crystals/kg

solution).  is the solute concentration in the liquid phase (kg API/kg solution), K& is the
density of crystalline API (assumed to be 1490 kg/m3),  is the minimum detectable

crystal size (m),  is the nucleation rate (# of nucleated crystals/kg solution∙s), and 86 is
the dimensionless crystal shape factor (t/6 for spheres) [196]. The units of the derivative
reduce to (kg of crystals/kg solution∙m external coordinate). In a pure mathematical
treatment,  would simply be set to zero; however, all instrumentation used in practice
for experimentation and process control will have limits to observability. When the
crystallization is below solubility, the mass balance becomes:
/! 3K& 86 OGf,!
=
/@
=>,!

Where O is the dissolution rate, explained in the section 0.

(6.4)
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6.6.1

Boundary Conditions

For the first segment ( = 1), the boundary conditions for these equations are:
:H (, @ = 0) = γH :

:H ( = 0, @) = ,HvPH

(6.5)

H (@ = 0) = γH 

Where : is the seed crystal size distribution,  is the nucleation rate (#/kg of solution∙s),
and  is the initial solute concentration. In subsequent segments ( ≥ 2), the boundary

conditions become:
#0%
:! (, @ = 0) = γ! :!H

:! ( = 0, @) = ,! vP!

(6.6)

#0%
! (@ = 0) = γ! !H

A Gaussian bell curve was used for : (#/kg of solution∙m) in all cases, with mean F##%

(meters) and standard deviation L##% (meters) (we would normally use the Greek letters

G and Æ for the mean and standard deviation, but these letters already correspond in this
work to the moments of the crystal size distribution and the supersaturation):
: () =



L##% Ç2t

exp −

( − F##% )f
®
2L##% f

(6.7)

Where  is the total number density (# of crystals/kg solution).  can be
interpreted in (6.7) as a constant that forces the seed distribution to agree with the
specified seed mass loading, _ (%, dimensionless). The mass balance on the seed

distribution is closed by solving the algebraic equation for  such that:
_ − K& 86 G, = 0

(6.8)
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Where G, is the third moment of the seed distribution. Equation (6.8) is closed by
manipulating  , which is embedded in the integral term G,:
r

G, =  :  /

(6.9)



6.6.2

Growth, Nucleation, and Dissolution Rate Laws

The growth and nucleation laws are given by the equations (again, alli subscripts refer to
the

J

segment):
P!  !  = 87

7
!

,!  !  = 89 Gf

9
!

O!  !  = −`87 (1 −
!

Where

= ! (@)/,!

!)

%

(6.10)

is the supersaturation ratio, 87 is the growth rate constant, T is the growth rate

order, 89 is the nucleation rate constant, S is the nucleation order, O is the dissolution
rate, / is the dissolution order, and  is the solubility concentration (kg API/kg

solution). P is replaced by O in (6.3) for

< i1, and / = 1 always in this work. We use a

modified version of the growth law for the dissolution rate law. The dissolution rate can
be approximated by multiplying the modified version of the growth law by a constant
` > 1, which adjusts for the fact that dissolution is typically much faster than growth.

The calculation of  is discussed in section 6.6.3. A summary of all fixed parameters
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related to equations (4.2) and (6.3) are given in Table 8 below. These variables were all
kept fixed during the optimization; decision variables are delineated further ahead.

Table 8 Physical and chemical property data table used for modeling the antisolvent
crystallization.
Parameter
Value
Initial concentration,  [kg API/kg solution,
0.030935
always saturated]
Shape factor, [-]
π/6
3
Solid API density, [kg/m ]
1490
Dissolution acceleration, φ [-]
250
Number of segments,  [-]
50
Seed crystal mean size, F##% [µm]
50
Seed crystal standard deviation, L##% [µm]
10

6.6.3

Calculation of API Solubility

The solubility of the API in a water-ethanol (solvent-antisolvent) mixture was taken from
the experimental data plot provided in Figure 2 of Luo et al. [196] for the case of the drug
biapenem. Data points were extracted from the curve using the DataToGraph utility, and
are given in Table 9 below [197]. Comparison with various curve fitting methods in
MATLAB showed that linear interpolation provided the best fit. The data correspond to a
minimum solubility in ethanol as 2.464 mg/ml, and a maximum solubility in water as
30.935 mg/ml.
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Table 9 Solubility data for biapenem-water-ethanol system.
Water Mass Fraction, Xw
0.199
0.299
0.398
0.500
0.599
0.699
0.799
0.898
1.000

The water mass fraction in the
!
*ÁÂ Ã

=

J

Csat x 103 (kg solute/kg solution)
2.464
2.831
3.497
4.463
6.103
9.615
15.299
21.956
30.935

PFC is computed by:
!

KÁÂ Ã ##% + KÁÂ Ã H

KÁÂ Ã ##% +

!
KÁÂ Ã H 



!

+ KÄÃÁ H 

(6.11)

!

Plugging *ÁÂ Ã into the curve fit object created in MATLAB yields the solubility

concentration of biapenem in segment , ,! .

6.7

Solution of Model Equations

A typical method used for solving equations (4.2) and (6.3) is to apply the method of
moments (MOM), which reduces system to a set of coupled ordinary differential
equations for the moments of the crystal size distribution. However, this method is
useless here, since we need the full CSD to be able to match the target distribution. To
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solve these equations, we have utilized a high-resolution finite volume (FV) technique,
which is the combination of the semi-discrete FV technique with the van Leer flux limiter
[113], [173]. This method provides Ê(ℎf ) accuracy where the solution is smooth, without
the oscillations found in other methods. Details on the finite volume method are given in
Majumder and Nagy [113].

6.8

Optimization Problem Formulation

Our goal is to eliminate the production of fine crystals by utilizing dissolution. The
quality of the elimination is ascertained by measuring how closely the attained number
fraction distribution leaving the  J PFC (1,#0% ) matches a theoretically-best growth-

only crystal size distribution, 1"7# . The target distribution is generated by simulating
the crystallization with only one segment, with nucleation arbitrarily set to zero. With no
nucleation, all solute depletion is solely due to crystal growth on the seeds, and no fine
crystals are ever created. Thus, the target distribution is a hypothetical best-case scenario
of pure growth achieved without nucleation. The closeness of matching can be expressed
in a least-squares sense. By manipulation of the antisolvent and solvent flowrates in each
segment (and other decision variables), we can make the fit between the model and the
target distribution tighter. The population and mass balance equations are solved for each
segment, and the output of one segment recursively becomes the input to the next
segment. The procedure begins anew, with fresh antisolvent flowing into the main flow
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stream. Population density and solute concentration are adjusted for the dilution induced
by addition of antisolvent at each mixing point.

6.8.1

Least-Squares Objective Function

The final number fraction distribution, 1 , is used for formulating the least-squares
problem:
:
[

Ë



µ16,,#0%
− 16,"7#


f

H

(6.12)

Where [ is the vector of decision variables (listed in Table 10), and 16,,#0% is the volume
fraction size distribution at the exit of the crystallizer. It is computed by:
1,#0% =

r

#0%
:

#0%
/
s :

(6.13)

The index  in (6.12) refers to a particular crystal size bin, with Q total bins. Note that :

integrates to : (the total number of crystals in the solution), while 1 integrates to 1.

We use the number fraction distribution instead of the number density, since the addition
of extra solvent and antisolvent causes dilution. In the previous work on cooling
crystallization by Majumder and Nagy [113], the least-squares function was formulated
in terms of volume density, :6 . In that work, there is no dilution effect, whereas in this

work the effect of dilution reduces :6 monotonically with each liquid addition. If :6 were

used to compute (6.12), it would be an “apples to oranges” comparison since total
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volumetric flow rates are not the same. Using the volume fraction distribution, 16 ,
however, abrogates this difficulty.

6.8.2

List of Decision Variables and Bound Constraints

All 2 + 5 decision variables in these optimizations had bound constraints. Table 10
below summarizes the decision variables and their lower/upper bounds.
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Table 10 Decision variables and bound constraints for in-situ fines dissolution
optimization.
Decision
Lower
Upper
Title
Units
Variable
Bound
Bound
##%

Feed flowrate of saturated
[ml/min]

0

300

Total flowrate of antisolvent

[ml/min]

0



Total flowrate of pure solvent

[ml/min]

0

300

/00#"

Inner diameter of crystallizer
[m]

10 × 10

25 × 10

[%, -]

2%

7%

[-]

0

1

[-]

0

1



_

solvent

tube
Seed mass loading

.H , .f , … , .

Antisolvent distribution

<H , <f , … , <

Pure solvent distribution

150

fractions

fractions

The optimization of the MSMA-PFC is known to be highly non-convex, as shown by the
landscape plots in Ridder et al. [161]. Such problems are not amenable to gradient search,
and so we have opted for a stochastic approach to circumvent the nonconvexity. The
genetic algorithm is a popular tool for solving optimization problems with this difficulty.
To make the GA operate more smoothly, our decision variables were fractions of the total
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antisolvent and total pure solvent. The flowrate into a segment

is the

J

fractional

distribution variable multiplied by total flow allotment.
! = .! 
!

6.8.3

= <!

(6.14)



Linear and Nonlinear Constraints

There were no linear inequalities in this study. The only linear constraints in this work are
two equalities, which require the apportionments of total liquid flows must each sum to
unity. The remaining six constraints are nonlinear inequalities. Table 11 below
summarizes these constraints.
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Table 11 Linear and nonlinear constraints for in-situ fines dissolution optimization.
Name
Constraint
Description
Type


ÌH

µ . = 1
!H

Total fractions of added liquid flows must


Ìf
Ì
Ì
Ì±

µ < = 1

Linear
sum to unity.

!H

Æ#0% − 1.05 ≤ 0
0.85 − Æ#0% ≤ 0



− 3600 ≤ 0

Final supersaturation is bracketed between
0.85 and 1.05.

Total residence time under 3600 seconds (1

Nonlinear

hour).
Ìe

0.30 − R ≤ 0

Minimum required crystal mass yield of
30%.

We require residence times of under 1 hour. In the multiple-cooling segment PFC array,
residence time is constant, since flowrate of liquor into each segment is always the same.
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However, the addition of antisolvent and pure solvent to the liquor flow changes
residence time into a nonlinear function:


=



=µ
!H

!


f
t/00#"
(@ /)

µ

4


!H ##%

!

1

+  H . +

Where @ /iis the length of a single segment. The
residence time for the

J

(6.15)

J



!H <

summand in (6.15) is the

segment, which is the segment’s volume divided by the total

flow rate through that segment. The total residence time is found by summing over all
individual residence times. Since each PFC volume is the same, it is taken out of the
summation distributively.

Drug API products are typically expensive, making wasted API a serious expense. We
require a crystal yield of at least 30% to trim unwise crystallization strategies from
consideration. Yield is calculated in the following manner:
R=

##% KÁÂ Ã  − (##% KÁÂ Ã +  KÁÂ Ã +  KÄÃÁ )#0%
##% KÁÂ Ã 

(6.16)

If #0% = 0 , then all of the solute has been crystallized, and thus R = 1 . If no

crystallization has occurred, the numerator will be zero, and thus R = 0. If seed crystals

have been dissolved due to excessive dissolution, then R becomes negative.
6.9

Solution of Least-Squares Problem by the Genetic Algorithm

The GA is less efficient compared to gradient-based methods, such as sequential
quadratic programming (SQP). However, algorithms like SQP are not robust to initial
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guess, and can become trapped in a sub-optimal local minimum [198], [199]. This is true
when the objective function and/or constraints are non-convex. Stochastic methods, such
as the GA or simulated annealing, are appropriate for nonconvex optimization. The
problem was solved by manipulating the 2 + 5 decision variables with the genetic
algorithm (GA). Each set of kinetic parameters and crystallizer lengths listed in Table 13
were optimized over to minimize the sum of the squares in (6.12). The GA initial
population was created by randomly sampling over the bounds given in Table 10 above.
The number of injections could not be used as a decision variable, as MATLAB’s genetic
algorithm cannot solve mixed-integer nonlinear programming (MINLP) problems that
have any type of equality constraint. The number of injections used was 50, which gave a
good tradeoff between curve fit and computation time. The population size was 750,
repeated for 25 generations. The MATLAB integrator, depending on the particular run,
was chosen for the quickest solution time. Either ode45, ode15s, or ode23 were used.

6.10 Results and Discussion
6.10.1 Experimental Design Array
To investigate the crystallizer’s performance for various kinetic parameters, a reduced
orthogonal array experimental design was used, with five factors, four levels, and 16 total
runs. The five factors are the nucleation and growth parameters, and the total crystallizer
length. The five factors and the four levels used are shown in Table 12 below.
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Table 12 Table of the five factors and four levels used for examining parameter space.
Growth
Total length
rate
Growth
Nucleation rate
Nucleation
of
constant order \
Level
constant, ÍÎ [#/m2∙s]
crystallizer,
order, Î [nd]
Í\
[nd]
3ÏÐÏÑÒ [m]
[µm/s]
1
2
3
4

1 × 10e
1 × 10¨
1 × 10©
1 × 10«

1
2
3
4

1 × 10¨

1

5

5 × 10¨

1.333

10

5 × 10e

2

20

1 × 10e

1.667

15

A reduced design was used, since exhaustive search over 45 = 1024 different
optimizations was computationally prohibitive. This experimental table is given in Table
13 below. The orthogonal array table allows for a good sampling of the search space with
only 16 samples instead of 1024.

161
Table 13 Experimental design table of factors and levels for the curve fit optimizations
conducted. The numbers correspond to the level column in Table 12. The sum of the
squares of the errors (SSE) and total amount of pure solvent added (Stotal) are given for
each run.
SSE
Í\
ÓÏÐÏÑÒ
Run #
ÍÎ
Î
\ 3ÏÐÏÑÒ
80
2.67E+07
1
1
1
1
1
1
0
4.71E+06
2
1
2
2
2
2
1.25E+07
1
3
1
3
3
3
3
1
7.58E+05
4
1
4
4
4
4
3
5.62E+08
5
2
1
2
3
4
7.42E+08
0
6
2
2
1
4
3
2
2.25E+07
7
2
3
4
1
2
0
6.93E+07
8
2
4
3
2
1
2.22E+09
8
9
3
1
3
4
2
2
2.10E+08
10
3
2
4
3
1
0
6.08E+09
11
3
3
1
2
4
3.10E+09
9
12
3
4
2
1
3
11
3.41E+09
13
4
1
4
2
3
7.82E+09
24
14
4
2
3
1
4
8.28E+09
25
15
4
3
2
4
1
16
1.27E+10
16
4
4
1
3
2
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Table 13 shows the experimental design matrix, as well as the resulting sum of the
squared errors for each curve fit to the zero-nucleation target distribution.

6.10.2 Volume Fraction Distributions for Optimized Cases
The data in Table 13 show that run #1 gave the tightest curve fit (Figure 6.4). The reason
for this tight curve fit is due to the system exhibiting low nucleation (the 89 level is at the
lowest level). Also in Figure 6.4 we show the performance of a single segment with
nucleation turned back on ( > 0). We can see there is little improvement observed
between MSMA-PFC and using a single segment.
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Figure 6.4 Volume-fraction distribution for run #1.
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Increasing values of 89 rapidly degrade the curve fit due to overwhelming nucleation.
Run #11 is representative of runs which are nucleation-dominated. As shown in Figure
6.5, there is a large amount of fines created, and the optimal result fails to hit the target
distribution. While we have improved the volume fraction distribution over the singlesegment case by producing less fines at the exit, there is still a great deal of fines
produced. The nucleation rate constant has the greatest effect upon the performance of
the crystallizer, indicating significant sensitivity to nucleation rate.
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Figure 6.5 Volume-fraction distribution for run #11, a nucleation-dominated case.
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6.10.3 Main-Factor Analysis
The results in section 6.10.2 suggest to us that the best results, intuitively, are obtained
when the system is growth-dominated. Main-factor analysis of the experimental matrix
confirms this suspicion. Main-factor analysis is done by taking the average of all SSE for
a given factor at the same level. For example, the average for the factor 89 at level 2
would take the average SSE of runs 5, 6, 7, and 8. This process is repeated for all five
factors and all four levels, which generates Table 14 below.

Table 14 Level-wise averages of SSE for each corresponding level and factor pair.
Í\
ÍÎ
Î
\
3ÏÐÏÑÒ
SSE
L1
L2
L3
L4

1.12E+07 1.56E+09 4.89E+09 2.74E+09 2.15E+09
3.49E+08 2.20E+09 2.99E+09 2.39E+09 3.74E+09
2.90E+09 3.60E+09 2.53E+09 3.38E+09 1.82E+09
8.06E+09 3.97E+09 9.11E+08 2.81E+09 3.62E+09

This analysis reveals to us what the most sensitive parameters are, and also what
combination of levels will theoretically provide the best curve fit – which we
hypothesized would be the growth-dominated case. We can see in Table 14 that the factor
89 spans the widest range of SSE values over the level averages. We thus conclude that

89 is the most sensitive parameter. Following the same line of reasoning, the second-
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most sensitive parameter is 87 . The optimal curve fit is projected to be the set of levels
for which SSE is a minimum for each corresponding factor. These values are shown in
boldface in Table 14 (they are the minimum values within each column). The main-factor
analysis projects that the tightest curve fit will be observed at a 89 of level 1, a S of level

1, a 87 of level 4, a T of level 2, and ani@ of level 3. We term this the “projected
optimum.” Note that this set of factors and levels is not present in Table 13. Solving the
optimization problem with this new set of parameters generates the volume fraction
distributions in Figure 6.6, which had an SSE of 4.83 × 10± , which is less than the

minimum of 7.58 × 10± in Table 13.
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Figure 6.6 Optimal fit predicted by analysis of the orthogonal array design.
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This result matches our intuition that the best result is obtained when nucleation is slow
and growth is fast. However, this has the effect of “cancelling out” the benefits of using
multiple injections, as we obtain a very tight fit to the curve anyways when using a single
injection for this set of kinetic parameters. There was no discernible trend observed with
respect to the optimized tube diameter. However, seed loading was typically between
5.0%-6.5%.

6.10.4 No Dissolution is Used to Control Fines
It is interesting (even if a bit disappointing) to observe that the optimization does not
want to use dissolution to get rid of fine crystals. The total amount of pure solvent added
during each optimization is given as the rightmost column in Table 13. Observe that little
to no pure solvent is ever added to the system for the optimal curve fits (observe in Table
10 that

 is

bounded on the left by zero). The supersaturation profiles ( vs. @ plots)

show barely any dissolution occurring. The supersaturation profile for the “project
optimum” is representative (Figure 6.7).
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Figure 6.7 Supersaturation profile for project optimum, representative of the other
supersaturation profiles.

Note how the supersaturation does not significantly (or at all) go below 1 anywhere in
Figure 6.7. This indicates to us that the situations in which the curve fit is superior to the
single-segment case (Figure 6.4 and Figure 6.5) is more likely due to the better control
offered by using multiple segments (and thus having finer control over supersaturation),
rather than making use of fines dissolution. The reason the optimization refuses to add
pure solvent in significant amounts is due to the fact that adding pure solvent reduces the
concentration (via dilution) and reduces available residence time (via equation (6.15)).
Reduced concentration reduces the available supersaturation, and reducing the residence
time reduces the time available for growth inside the MSMA-PFC. Thus, despite the
potential for dissolving fines, the benefit of adding pure solvent does not counterbalance
the other two negative phenomena.
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6.11 Summary and Conclusions
We have investigated the use of the MSMA-PFC, run in antisolvent mode, for the
growing of crystals while dissolving fines in-situ. The model equations solved were the
partial differential population balance equation and the integro-differential mass balance
equation. The solution method used was the finite volume method, since the entire CSD
was required to calculate the sum of the squared errors for the curve fit. The final CSD
was compared to a target CSD generated by arbitrarily setting nucleation to zero. A
reduced orthogonal array experimental design was used to examine the effect of several
kinetic parameters and total crystallizer length. The genetic algorithm was used to
optimize over the decision variables, with the parameters from the experimental design
held constant. The results indicate that 89 is the most sensitive parameter, followed by 87 .
As 89 increases, the curve fit degrades rapidly due to becoming overwhelmed by
nucleation. Examination of the supersaturation profiles shows that dissolution is not
occurring appreciably for any of the optimizations performed. The MSMA-PFC performs
best under kinetic crystallization conditions in which a single PFC also works sufficiently
well. There are situations where using multiple additions does improve the curve fit
versus the single-segment case, but excessive fines still exist. The reason the optimization
does not add any pure solvent is likely due to the addition of pure solvent causing a
simultaneous decrease in concentration and decrease in residence time. Both of these
cause the optimization to take “one step forward and two steps back”, thus adding pure
solvent is judged to be sub-optimal.
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CHAPTER 7. SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS

7.1

Summary and Conclusions

The aim of this research was to investigate a new methods of producing pharmaceutical
drugs using computational methods. The drug industry is undergoing a major shift in the
way it thinks about manufacturing. Prior batch methods of manufacturing are expensive
and wasteful, while continuous methods are much more efficient. This motivates the
study of novel crystallizers. As an example, we have investigated the optimal operation
and optimal design of a new type of crystallizer, the multi-segment, multi-addition plug
flow crystallizer, or MSMA-PFC.

The literature review began our work. We started with a general overview of current
problems in drug manufacture, and new technologies being investigated to address these
problems. We discussed many of the interesting new technologies being pursued in the
areas of synthesis, purification, and formulation of pharmaceuticals.

An especially important unit operation is crystallization, from which the vast majority of
drugs are separated and purified. As discussed in CHAPTER 3, many new technologies
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for

continuous

crystallization

are

being

investigated

for

application

toward

pharmaceutical purification.

In CHAPTER 4, we discuss one such technology in great detail. This crystallizer uses
multiple plug-flow elements in series, which allows for finer control of supersaturation in
one dimension. We have investigated the use of a multi-segment, multi-addition plug
flow crystallizer (MSMA-PFC) for the production of pharmaceutical API crystals via
computational methods. We have also shown that the optimization is nonconvex, and is
not amenable to gradient search methods. Instead, we have utilized the genetic algorithm
to optimize the decision variables. A multiobjective optimization problem was solved to
investigate the performance of the crystallizer. The crystallization system was simulated
by solving the population balance and mass balance equations using, depending on
circumstance, either the method-of-moments or the finite-volume method. The system is
run exclusively at steady-state as an antisolvent crystallization. The decision variables
(among others) are the flowrates of antisolvent (and if applicable, pure solvent) into each
distinct segment. In this simplified case, we have examined the tradeoff between massmean crystal size and coefficient of variation – though a variety of other objective
functions could be used to extend the framework further. Our results showed that
rigorous optimization was able to generate superior designs to what was shown in prior
literature. Using the Monte-Carlo method, we examined in greater detail the robustness of
the crystallizer with respect to error in kinetic parameters and antisolvent flowrate. The
results indicate that there is significant sensitivity to kinetic parameters, though the
relationship to the nucleation rate constant is somewhat counterintuitive. We furthermore
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find significant sensitivity with respect to antisolvent flowrate. Error is magnified when
multiple stages are in error simultaneously.

In CHAPTER 5 We have introduced in this work a new framework for optimizing plug
flow crystallization systems, which was lacking previously in the literature. Specifically,
we have developed a combined model and optimization framework for identifying
optimal designs of the MSMA-PFC. The methodology worked by splitting the MSMAPFC into progressively greater numbers of segments, and optimizing mass-mean crystal
size (or coefficient of variation) over the antisolvent profile. Our first study in this
chapter used the same total flowrates as in CHAPTER 4 Results show that multiple
modes in the distribution are observed when maximizing  , but generally a much
smoother distribution is obtained when minimizing . This behavior persists when feed

flowrate and total antisolvent are incorporated as decision variables as well. For the
second part of our study, we permitted total antisolvent flowrate and feed flowrate to be
decision variables. Under these circumstances, residence time tends to be independent of
optimization objective. Using the finite volume method, the crystal size distributions
show multiple modes are present when maximizing  , but typically unimodal when

minimizing . Greatest control (tending toward larger crystal size) was observed when

using 25 injections, as agrees with intuition. Antisolvent distribution is different when
maximizing either  or , though in both cases antisolvent sends to be distributed in a
wide manner across the injections, with almost no injections receiving > 10% of the total
antisolvent.
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In CHAPTER 6, we examined the use of the MSMA-PFC for the production crystals
while dissolving fine crystals in-situ. The results show that the optimization actually does
not want to dissolve the fine crystals in order to match the CSD. Optimization results
routinely set pure solvent flow to either zero or small values compared to the feed
flowrate and total antisolvent flowrate. We have used an orthogonal array experimental
design to sample the parameter space over the nucleation and growth rate parameters, as
well as the total crystallizer length. Single-factor analysis of the orthogonal array
predicted the intuitive result that the best performance would be observed for the case of
slow nucleation and fast growth. Using the parameters predicted from the single-factor
analysis, we find that the best results are obtained for smallest values of 89 (low
nucleation) and highest values of the growth constant, 87 . The most sensitive parameter

is 89 , followed by 87 . The problem with this situation, is that when compared to using a
single segment, there is virtually no improvement in performance, e.g. the system was
already well-behaved to begin with. The best use of in-situ fines dissolution would be for
the crystallization of low-nucleation systems. For moderate nucleation cases, the MSMAPFC results do show improvement over the nucleating case, but still exhibit large
amounts of fine crystals. At higher levels of nucleation, the systems becomes
overwhelmed with fines. Examination of the supersaturation profiles reveals that the
optimization does not make use of dissolution in any of the cases for fines removal. This
is in contrast to the work by Majumder and Nagy [113] on in-situ fines dissolution using
a cooling crystallization, which clearly showed the dissolution of fine crystals. The
reason we believe that antisolvent crystallization fails to make use of dissolution by the
addition of pure solvent is because the addition of pure solvent causes too much loss of
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supersaturation due to the effect of dilution. Furthermore, the addition of pure solvent
simultaneously decreases the available residence time for crystallization. Thus, the
addition of pure solvent causes us to “take one step forward and two steps back.”

7.2

Future Directions

A variety of extensions of this work are possible. An important next step would be
experimental verification of the optimal result found in CHAPTER 4 using a lab-scale
plug flow crystallization system. Another possible direction is robust optimization of the
flufenamic acid crystallization using a minimax framework. The idea here is to attempt to
maximize the mean crystal size, but also to simultaneously minimize the mean size by
manipulating experimental parameters over their uncertainty bounds. The results of this
study would indicate how robust the crystallization process is to parametric uncertainty.
Unsteady-state simulation and optimization of the plug flow crystallizer. In this study,
time-optimal control could be used to optimize a variety of objectives for optimizing the
startup of the PFC, e.g. minimizing the mass of wasted API. Dynamical analysis of the
unsteady state MSMA-PFC is another future direction. In this study, variations in
important parameters could reveal the presence of dynamical anomalies and bifurcations,
or even chaotic behavior. Residence time effects are also of great importance. Our
simulations always assumed plug flow, but incorporating a residence time distribution
model into the framework would allow for better predictive capabilities. Chemical
fouling is a known problem in the operation of plug flow crystallizers. This is when API
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begins to crystallize and accumulate on the vessel walls. This interferes with heat transfer,
and over the long term can reduce residence time by reducing total volume. A strategy is
needed for the removal of fouling areas once they begin to accumulate, or for a way to
operate the crystallization such that fouling does not occur. Economic analysis of a plant
using an MSMA-PFC array is another future direction. A comparison between
conventional batch technology and MSMPR modes would clearly show which
technology was more economically viable. Such analysis for the case of MSMPR
crystallization has already been done by Schaber et al. [5]. In this work, we have
investigated solely antisolvent crystallization, but it is possible to utilize cooling and
antisolvent crystallization simultaneously. Instead of a solubility curve, we now have a
solubility surface with respect to temperature and antisolvent ratio. This allows for a new,
independent actuator for the control of supersaturation. Polymorphism and chirality are of
serious concern in drug crystallization. Synthesis of the incorrect solid or optical form
will, in the best case scenario, lead to an inactive medication. In the worst case scenario,
the resulting compound will be a deadly toxin. The extension of the framework in this
work for the optimization of polymorphic form content and of optical form are another
possible future direction. Significant interaction is known to exist between upstream and
downstream processes in pharmaceutical manufacture. Another possible future direction
would be to integrate other unit operations into the crystallization, such as filtration,
washing, and drying. The final goal would be to optimize the properties of the final dry
crystals produced at the exit of the crystallization section. Crystal shape is also of great
importance in drug manufacture. In this work, we have only used a 1-dimension
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population balance. However, two-dimensional population balances are becoming more
commonly applied to shape control.
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